{ "$schema_version": "5.3", "review_mode": "fresh", "claim_restatement": { "index_wording": "Amyloid Cascade Hypothesis", "entry_form": "phenomenon", "gradeable_restatement": "Aβ accumulation is the primary upstream driver of Alzheimer's disease, initiating tau pathology, synaptic failure and progressive neurodegeneration in familial and sporadic disease.", "restatement_required": true, "split_into": [], "parent_claim": null, "scope_qualifiers": [ { "qualifier": "Baseline disease stage, genotype, age, dose and setting", "determinable_before_outcome": true, "determined_from": "Enrollment facts and preregistration; failed predictions are not excluded as nonresponders.", "action": "retained" } ] }, "hypothesis": { "name": "Amyloid Cascade Hypothesis", "central_claim": "Aβ accumulation is the primary upstream driver of Alzheimer's disease, initiating tau pathology, synaptic failure and progressive neurodegeneration in familial and sporadic disease.", "proposed_mechanism": "Aβ accumulation is the primary upstream driver of Alzheimer's disease, initiating tau pathology, synaptic failure and progressive neurodegeneration in familial and sporadic disease.", "claimed_scope": "disease-class", "claimed_level": [ "initiation", "progression" ], "is_conjunctive": true, "conjunctive_note": "The index prescribes scope-matched assessment; SC4 carries the full sporadic primacy/generalization scope. SC5 is an added narrower therapeutic subclaim and cannot carry initiation." }, "rubric_routing": { "primary_rubric": "01-neurodegeneration.md", "secondary_rubrics": [ "05-immunology-inflammation.md" ], "index_notes_applied": [ "The index prescribes scope-matched assessment; SC4 carries the full sporadic primacy/generalization scope. SC5 is an added narrower therapeutic subclaim and cannot carry initiation." ], "rubric_fit_note": "Exact archived v5.3 framework and index used. Actual experimental scope and human generalization are adjudicated separately." }, "subclaim_matrix": { "subclaims": [ { "id": "SC1", "statement": "Aβ plaque accumulation is the primary driver of neurodegeneration in AD.", "subclaim_type": "primacy", "scope": "familial and sporadic AD", "claimed_scope": "familial and sporadic AD", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Clinical trajectory following selective plaque perturbation", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "See quoted boundary and threshold audit below; full claimed scope retained.", "rationale": "Plaque-targeting treatment changes early clinical trajectories, but a primary plaque-specific initiation mechanism is not isolated across AD. Plaques, soluble aggregates and immune clearance are not interchangeable mediators." }, { "id": "SC2", "statement": "Soluble Aβ oligomers are the causally active species.", "subclaim_type": "mechanism", "scope": "AD-related injury, with human attribution scored separately", "claimed_scope": "AD-related injury, with human attribution scored separately", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Oligomer-selective depletion with plaque burden preserved", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "See quoted boundary and threshold audit below; full claimed scope retained.", "rationale": "Human extracts and selective model manipulations support soluble Aβ toxicity. BACE1 suppression is not oligomer-selective, and human CSF oligomer engagement has not isolated oligomer-specific clinical mediation. Defined mouse hyperactivity causality is retained separately at Ε." }, { "id": "SC3", "statement": "Aβ is upstream of tau in the pathogenic cascade.", "subclaim_type": "primacy", "scope": "familial and sporadic AD", "claimed_scope": "familial and sporadic AD", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Aβ perturbation preventing or delaying tau and clinical injury", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "See quoted boundary and threshold audit below; full claimed scope retained.", "rationale": "Amyloid can facilitate model injury and modulate tau markers; wider tau spread associates with amyloid in people. Early medial-temporal tau, human resilience, regional/null downstream responses and absent selective human mediation limit universal temporal primacy." }, { "id": "SC4", "statement": "Familial Aβ-cascade causality generalizes to sporadic AD as its primary initiating explanation.", "subclaim_type": "generalization", "scope": "sporadic AD across baseline disease stages", "claimed_scope": "sporadic AD across baseline disease stages", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Human genetics and clinical intervention separating contribution from initiation/primacy", "hsef_level": "Γ", "confidence": "Moderate", "governing_cap_or_threshold": "See quoted boundary and threshold audit below; full claimed scope retained.", "rationale": "Lifelong APP processing instruments and early-AD randomized clinical effects establish more than association, but neither proves that the full familial primary-initiation cascade explains sporadic disease across stages. This is the scope-matched gate." }, { "id": "SC5", "statement": "Amyloid-directed intervention changes clinical trajectory in biomarker-confirmed early symptomatic AD.", "subclaim_type": "mechanism", "scope": "baseline amyloid-positive MCI or mild dementia due to AD", "claimed_scope": "baseline amyloid-positive MCI or mild dementia due to AD", "governing_rubric": "01-neurodegeneration.md", "key_evidence_anchor": "Randomized clinical outcomes with target engagement", "hsef_level": "Ε", "confidence": "Moderate", "governing_cap_or_threshold": "See quoted boundary and threshold audit below; full claimed scope retained.", "rationale": "Positive lecanemab and donanemab clinical comparisons cross Δ, with a defined early amyloid-positive symptomatic population and contrasting stages/agents. Ε records mapped context and pharmacology boundaries. Antibody replications alone are one mechanistic modality; familial instruments do not independently establish this specific treatment subclaim." } ], "aggregation_rule": "scope-matched", "aggregation_preregistered": true, "aggregation_rationale": "The index prescribes scope-matched assessment; SC4 carries the full sporadic primacy/generalization scope. SC5 is an added narrower therapeutic subclaim and cannot carry initiation.", "primary_subclaim_id": "SC4", "aggregation_derivation": "Scope-matched SC4 returns Γ for primary initiation/generalization; SC5 separately returns Ε for early clinical contribution. Human genetics and clinical perturbations are considered together and are not re-capped as mere association. Their convergence supports bounded amyloid contribution, while sole/primary initiation and exact pathogenic-species mediation remain unresolved.", "aggregation_alternatives": { "weakest_link_would_return": "Γ", "primary_subclaim_would_return": "Γ", "scope_matched_would_return": "Γ", "note": "Sensitivities use preregistered full-scope gate SC4; narrow successes are not permitted to replace it." }, "index_rule_deviation": "" }, "competing_models": { "models_evaluated": [ { "rank_in_tournament": 1, "model_id": "M5", "is_nominal": false, "name": "Heterogeneous multi-hit AD", "core_claim": "Multiple interacting initiating and amplifying pathways produce AD trajectories, with context-dependent amyloid contribution.", "explains_what_nominal_does_not": "Multiple interacting initiating and amplifying pathways produce AD trajectories, with context-dependent amyloid contribution.", "strongest_supporting_evidence": [ "Mixed pathology, familial/sporadic differences, resilience and clinical stage dependence fit heterogeneity." ], "strongest_contradictory_evidence": [ "A flexible multi-hit model can absorb observations without a uniquely discriminating intervention; it is not itself proved." ], "hsef_level_for_this_model": "Γ", "rationale": "Mixed pathology, familial/sporadic differences, resilience and clinical stage dependence fit heterogeneity. A flexible multi-hit model can absorb observations without a uniquely discriminating intervention; it is not itself proved." }, { "rank_in_tournament": 2, "model_id": "M1", "is_nominal": true, "name": "Amyloid-primary cascade", "core_claim": "Amyloid accumulation is the primary initiating driver upstream of tau and clinical injury across AD.", "explains_what_nominal_does_not": "Amyloid accumulation is the primary initiating driver upstream of tau and clinical injury across AD.", "strongest_supporting_evidence": [ "APP genetics, knock-in/conditional perturbations and positive clinical antibodies support a causal contribution." ], "strongest_contradictory_evidence": [ "Prevention/agent nulls, nonuniform tau order and unisolated human species/primacy block the complete initiating claim." ], "hsef_level_for_this_model": "Γ", "rationale": "APP genetics, knock-in/conditional perturbations and positive clinical antibodies support a causal contribution. Prevention/agent nulls, nonuniform tau order and unisolated human species/primacy block the complete initiating claim." }, { "rank_in_tournament": 3, "model_id": "M2", "is_nominal": false, "name": "Tau-primary/selective vulnerability", "core_claim": "Tau-associated injury and neuronal vulnerability determine degeneration; amyloid facilitates rather than universally initiates it.", "explains_what_nominal_does_not": "Tau-associated injury and neuronal vulnerability determine degeneration; amyloid facilitates rather than universally initiates it.", "strongest_supporting_evidence": [ "Tau reduction with amyloid preserved and tau-linked atrophy/resilience support a proximate injury role." ], "strongest_contradictory_evidence": [ "Model rescue does not demonstrate tau is the earliest human initiating event; amyloid-directed clinical benefits constrain an amyloid-inert account." ], "hsef_level_for_this_model": "Γ", "rationale": "Tau reduction with amyloid preserved and tau-linked atrophy/resilience support a proximate injury role. Model rescue does not demonstrate tau is the earliest human initiating event; amyloid-directed clinical benefits constrain an amyloid-inert account." }, { "rank_in_tournament": 4, "model_id": "M4", "is_nominal": false, "name": "Vascular/clearance failure", "core_claim": "Vascular and clearance disturbances drive some injury and amyloid retention.", "explains_what_nominal_does_not": "Vascular and clearance disturbances drive some injury and amyloid retention.", "strongest_supporting_evidence": [ "APOE4 BBB prognosis and endothelial/model perturbations support a vascular contribution." ], "strongest_contradictory_evidence": [ "Human observational prediction and 5xFAD endothelial biology do not establish vascular primacy for all AD." ], "hsef_level_for_this_model": "Γ", "rationale": "APOE4 BBB prognosis and endothelial/model perturbations support a vascular contribution. Human observational prediction and 5xFAD endothelial biology do not establish vascular primacy for all AD." }, { "rank_in_tournament": 5, "model_id": "M3", "is_nominal": false, "name": "Inflammatory initiation", "core_claim": "Glial innate pathways initiate injury and drive amyloid/tau downstream.", "explains_what_nominal_does_not": "Glial innate pathways initiate injury and drive amyloid/tau downstream.", "strongest_supporting_evidence": [ "STING-related functional intervention and glial marker coupling support inflammatory involvement." ], "strongest_contradictory_evidence": [ "Pathway blockade can interrupt amplification without proving first initiation; the human marker results remain observational." ], "hsef_level_for_this_model": "Γ", "rationale": "STING-related functional intervention and glial marker coupling support inflammatory involvement. Pathway blockade can interrupt amplification without proving first initiation; the human marker results remain observational." } ], "tournament_summary": "The ranked comparison is descriptive evidence adjudication; it never changes the nominal level. APOE3 Christchurch heterozygosity (PMID38899694) separates the heterogeneous model from a simple plaque-primary trajectory: delayed impairment and limited tau occur despite appreciable plaque in selected autopsies. This is a bounded natural contrast, not definitive universal refutation.", "study_separating_rank1_from_rank2": "APOE3 Christchurch heterozygosity (PMID38899694) separates the heterogeneous model from a simple plaque-primary trajectory: delayed impairment and limited tau occur despite appreciable plaque in selected autopsies. This is a bounded natural contrast, not definitive universal refutation.", "nominal_wins_only_by_funding_artifact": false, "level_unchanged_by_tournament": true }, "evidence_inventory": [ { "n": 1, "pmid": "36449413", "title": "Lecanemab in Early Alzheimer's Disease.", "citation": "van Dyck CH, Swanson CJ, Aisen P et al. Lecanemab in Early Alzheimer's Disease. The New England journal of medicine. 2023.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36449413/", "url": "https://pubmed.ncbi.nlm.nih.gov/36449413/", "doi": "10.1056/NEJMoa2212948", "pmcid": "", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT03887455", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Lecanemab slowed cognitive and functional decline in amyloid-confirmed early AD, with adverse events.", "what_it_does_not_show": "Clinical slowing does not establish complete mediation, universal initiation, halt or reversal of disease.", "confounders_present": [ "Clinical slowing does not establish complete mediation, universal initiation, halt or reversal of disease." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 2, "pmid": "37459141", "title": "Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.", "citation": "Sims JR, Zimmer JA, Evans CD et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37459141/", "url": "https://pubmed.ncbi.nlm.nih.gov/37459141/", "doi": "10.1001/jama.2023.13239", "pmcid": "PMC10352931", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT04437511", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Donanemab favored clinical outcomes in early symptomatic amyloid/tau-positive AD.", "what_it_does_not_show": "Both groups worsened; this is stage-specific contribution rather than proof of a sole initiator.", "confounders_present": [ "Both groups worsened; this is stage-specific contribution rather than proof of a sole initiator." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 3, "pmid": "37966285", "title": "Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.", "citation": "Bateman RJ, Smith J, Donohue MC et al. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. The New England journal of medicine. 2023.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37966285/", "url": "https://pubmed.ncbi.nlm.nih.gov/37966285/", "doi": "10.1056/NEJMoa2304430", "pmcid": "PMC10794000", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID37966285", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3", "SC5" ], "favors_models": [ "M5" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "Gantenerumab reduced plaque and fluid tau markers without significant primary clinical slowing in either GRADUATE trial.", "what_it_does_not_show": "Incomplete plaque removal and target/stage differences limit a universal null inference; tau PET was similar.", "confounders_present": [ "Incomplete plaque removal and target/stage differences limit a universal null inference; tau PET was similar." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 4, "pmid": "35542991", "title": "Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.", "citation": "Budd Haeberlein S, Aisen PS, Barkhof F et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. The journal of prevention of Alzheimer's disease. 2022.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/35542991/", "url": "https://pubmed.ncbi.nlm.nih.gov/35542991/", "doi": "10.14283/jpad.2022.30", "pmcid": "", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID35542991", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "Aducanumab's EMERGE clinical comparison was positive and ENGAGE was null despite marker engagement in both.", "what_it_does_not_show": "Discordance, early futility stopping and exposure differences prevent treating the pair as consistent clinical replication.", "confounders_present": [ "Discordance, early futility stopping and exposure differences prevent treating the pair as consistent clinical replication." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 5, "pmid": "37458272", "title": "Trial of Solanezumab in Preclinical Alzheimer's Disease.", "citation": "Sperling RA, Donohue MC, Raman R et al. Trial of Solanezumab in Preclinical Alzheimer's Disease. The New England journal of medicine. 2023.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37458272/", "url": "https://pubmed.ncbi.nlm.nih.gov/37458272/", "doi": "10.1056/NEJMoa2305032", "pmcid": "PMC10559996", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID37458272", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M5" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "Solanezumab did not slow preclinical cognitive decline; amyloid PET increased in both arms.", "what_it_does_not_show": "Monomer targeting and incomplete prevention of deposition do not test complete plaque eradication.", "confounders_present": [ "Monomer targeting and incomplete prevention of deposition do not test complete plaque eradication." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 6, "pmid": "29365294", "title": "Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.", "citation": "Honig LS, Vellas B, Woodward M et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. The New England journal of medicine. 2018.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29365294/", "url": "https://pubmed.ncbi.nlm.nih.gov/29365294/", "doi": "10.1056/NEJMoa1705971", "pmcid": "", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID29365294", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M5" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "Solanezumab did not meet its mild-AD primary clinical endpoint.", "what_it_does_not_show": "Hierarchical secondary outcomes were descriptive; this agent's null does not erase antibody-specific positives.", "confounders_present": [ "Hierarchical secondary outcomes were descriptive; this agent's null does not erase antibody-specific positives." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 7, "pmid": "29719179", "title": "Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease.", "citation": "Egan MF, Kost J, Tariot PN et al. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. The New England journal of medicine. 2018.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/29719179/", "url": "https://pubmed.ncbi.nlm.nih.gov/29719179/", "doi": "10.1056/NEJMoa1706441", "pmcid": "PMC6776074", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT01739348", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "Verubecestat did not improve cognitive or functional decline in mild-to-moderate AD and increased adverse events.", "what_it_does_not_show": "BACE inhibition affects non-Aβ substrates and is not a selective experiment on pathological aggregates.", "confounders_present": [ "BACE inhibition affects non-Aβ substrates and is not a selective experiment on pathological aggregates." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 8, "pmid": "30970186", "title": "Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.", "citation": "Egan MF, Kost J, Voss T et al. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. The New England journal of medicine. 2019.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30970186/", "url": "https://pubmed.ncbi.nlm.nih.gov/30970186/", "doi": "10.1056/NEJMoa1812840", "pmcid": "PMC6776078", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT01953601", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "contradicts", "what_it_shows": "Prodromal verubecestat was ineffective and the higher dose worsened the primary clinical outcome.", "what_it_does_not_show": "Early stopping, BACE substrate pleiotropy and drug harms prevent equating this with selective Aβ harm removal.", "confounders_present": [ "Early stopping, BACE substrate pleiotropy and drug harms prevent equating this with selective Aβ harm removal." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 9, "pmid": "33464300", "title": "Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial.", "citation": "Sperling R, Henley D, Aisen PS et al. Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial. JAMA neurology. 2021.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33464300/", "url": "https://pubmed.ncbi.nlm.nih.gov/33464300/", "doi": "10.1001/jamaneurol.2020.4857", "pmcid": "PMC7816119", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID33464300", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "Atabecestat caused dose-related cognitive worsening with evidence of reversibility after withdrawal.", "what_it_does_not_show": "A truncated hepatic-safety-stopped trial does not isolate the specific Aβ versus other BACE-dependent functions.", "confounders_present": [ "A truncated hepatic-safety-stopped trial does not isolate the specific Aβ versus other BACE-dependent functions." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 10, "pmid": "31764959", "title": "Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials.", "citation": "Wessels AM, Tariot PN, Zimmer JA et al. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials. JAMA neurology. 2020.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31764959/", "url": "https://pubmed.ncbi.nlm.nih.gov/31764959/", "doi": "10.1001/jamaneurol.2019.3988", "pmcid": "PMC6902191", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID32658253" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "AMARANTH+DAYBREAK", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "Lanabecestat failed to slow clinical decline in AMARANTH and DAYBREAK.", "what_it_does_not_show": "Premature termination and substrate specificity constrain the mechanistic inference; a PET-sign erratum is attached.", "confounders_present": [ "Premature termination and substrate specificity constrain the mechanistic inference; a PET-sign erratum is attached." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 11, "pmid": "33720637", "title": "Donanemab in Early Alzheimer's Disease.", "citation": "Mintun MA, Lo AC, Duggan Evans C et al. Donanemab in Early Alzheimer's Disease. The New England journal of medicine. 2021.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33720637/", "url": "https://pubmed.ncbi.nlm.nih.gov/33720637/", "doi": "10.1056/NEJMoa2100708", "pmcid": "", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT03367403", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Phase-2 donanemab favored its primary integrated clinical score; most secondary comparisons were mixed.", "what_it_does_not_show": "This primary contrast is not the same as all participants in later post-hoc analyses, and tau change was small globally.", "confounders_present": [ "This primary contrast is not the same as all participants in later post-hoc analyses, and tau change was small globally." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 12, "pmid": "36094645", "title": "Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial.", "citation": "Shcherbinin S, Evans CD, Lu M et al. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA neurology. 2022.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36094645/", "url": "https://pubmed.ncbi.nlm.nih.gov/36094645/", "doi": "10.1001/jamaneurol.2022.2793", "pmcid": "PMC9468959", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT03367403", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Post-hoc donanemab analyses linked clearance to regional tau slowing and clinical model effects in APOE4 carriers.", "what_it_does_not_show": "Postrandomization associations and model forecasts are not randomized mediator manipulation or a new trial.", "confounders_present": [ "Postrandomization associations and model forecasts are not randomized mediator manipulation or a new trial." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 13, "pmid": "31168802", "title": "Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid.", "citation": "Yang T, Dang Y, Ostaszewski B et al. Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid. Annals of neurology. 2019.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/31168802/", "url": "https://pubmed.ncbi.nlm.nih.gov/31168802/", "doi": "10.1002/ana.25513", "pmcid": "PMC6771589", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "ABBY+BLAZE", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Crenezumab lowered measured CSF oligomer levels in phase-2 trial specimens.", "what_it_does_not_show": "Fluid target engagement does not establish brain-species selective depletion or clinical efficacy.", "confounders_present": [ "Fluid target engagement does not establish brain-species selective depletion or clinical efficacy." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 14, "pmid": "27176461", "title": "Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.", "citation": "Vandenberghe R, Rinne JO, Boada M et al. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimer's research & therapy. 2016.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27176461/", "url": "https://pubmed.ncbi.nlm.nih.gov/27176461/", "doi": "10.1186/s13195-016-0189-7", "pmcid": "PMC4866415", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID27176461", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC5" ], "favors_models": [ "M5" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "Two terminated global bapineuzumab trials were null for clinical outcomes and their examined biomarker contrasts.", "what_it_does_not_show": "Dose, stage and absent biomarker movement limit claims that successful selective removal was clinically ineffective.", "confounders_present": [ "Dose, stage and absent biomarker movement limit claims that successful selective removal was clinically ineffective." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 15, "pmid": "22801501", "title": "A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.", "citation": "Jonsson T, Atwal JK, Steinberg S et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/22801501/", "url": "https://pubmed.ncbi.nlm.nih.gov/22801501/", "doi": "10.1038/nature11283", "pmcid": "", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID22801501", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "natural experiment", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "APP A673T was associated with protection and reduced amyloidogenic processing in functional assays.", "what_it_does_not_show": "A rare lifelong processing variant is stronger than pathology co-occurrence but does not isolate every APP product or all sporadic cases.", "confounders_present": [ "A rare lifelong processing variant is stronger than pathology co-occurrence but does not isolate every APP product or all sporadic cases." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 16, "pmid": "1671712", "title": "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.", "citation": "Goate A, Chartier-Harlin MC, Mullan M et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/1671712/", "url": "https://pubmed.ncbi.nlm.nih.gov/1671712/", "doi": "10.1038/349704a0", "pmcid": "", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID1671712", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "natural experiment", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "An APP missense variant segregated with early-onset familial AD in two unrelated families.", "what_it_does_not_show": "The instrument concerns selected familial disease, not all late-onset sporadic initiation.", "confounders_present": [ "The instrument concerns selected familial disease, not all late-onset sporadic initiation." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 17, "pmid": "16369530", "title": "APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy.", "citation": "Rovelet-Lecrux A, Hannequin D, Raux G et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nature genetics. 2006.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/16369530/", "url": "https://pubmed.ncbi.nlm.nih.gov/16369530/", "doi": "10.1038/ng1718", "pmcid": "", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID16369530", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "natural experiment", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "APP-locus duplications occurred in families with early-onset AD and prominent cerebral amyloid angiopathy.", "what_it_does_not_show": "Gene dosage affects the precursor and vascular/parenchymal biology, not exclusively plaque toxicity.", "confounders_present": [ "Gene dosage affects the precursor and vascular/parenchymal biology, not exclusively plaque toxicity." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 18, "pmid": "41579901", "title": "Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial.", "citation": "Tariot PN, Lopera FS, Ríos-Romenets S et al. Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet. Neurology. 2026.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41579901/", "url": "https://pubmed.ncbi.nlm.nih.gov/41579901/", "doi": "10.1016/S1474-4422(25)00426-0", "pmcid": "PMC12994566", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID41579901", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M5" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "The completed Colombian crenezumab prevention trial found no significant benefit on either primary clinical endpoint and no clear plaque-removal effect.", "what_it_does_not_show": "It cannot be described as a successful plaque-clearance prevention test; limited engagement constrains interpretation.", "confounders_present": [ "It cannot be described as a successful plaque-clearance prevention test; limited engagement constrains interpretation." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 19, "pmid": "38899694", "title": "APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease.", "citation": "Quiroz YT, Aguillon D, Aguirre-Acevedo DC et al. APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease. The New England journal of medicine. 2024.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/38899694/", "url": "https://pubmed.ncbi.nlm.nih.gov/38899694/", "doi": "10.1056/NEJMoa2308583", "pmcid": "PMC12640232", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID38899694", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status record; selected primary-body sections: S7, S13, S14. No full-paper or supplement audit.", "relates_to_subclaims": [ "SC1", "SC3", "SC4" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "natural experiment", "decisive_perturbation": true, "endogenous": true, "direction": "contradicts", "what_it_shows": "APOE3 Christchurch heterozygotes in the PSEN1 kindred had delayed impairment; selected autopsies showed substantial plaque with limited tau.", "what_it_does_not_show": "Related-kindred sampling, sparse imaging/autopsy and qualitative unquantified pathology do not prove amyloid is causally irrelevant.", "confounders_present": [ "Related-kindred sampling, sparse imaging/autopsy and qualitative unquantified pathology do not prove amyloid is causally irrelevant." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 20, "pmid": "28350801", "title": "APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases.", "citation": "Lanoiselée HM, Nicolas G, Wallon D et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS medicine. 2017.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28350801/", "url": "https://pubmed.ncbi.nlm.nih.gov/28350801/", "doi": "10.1371/journal.pmed.1002270", "pmcid": "PMC5370101", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID28350801", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Early-onset screening identified familial and de novo APP/presenilin variants, including apparently sporadic presentations.", "what_it_does_not_show": "Apparently sporadic early-onset mutation carriers are not equivalent to general late-onset sporadic AD; some variant pathogenicity was unresolved.", "confounders_present": [ "Apparently sporadic early-onset mutation carriers are not equivalent to general late-onset sporadic AD; some variant pathogenicity was unresolved." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 21, "pmid": "30980041", "title": "Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta.", "citation": "Arber C, Toombs J, Lovejoy C et al. Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Molecular psychiatry. 2020.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/30980041/", "url": "https://pubmed.ncbi.nlm.nih.gov/30980041/", "doi": "10.1038/s41380-019-0410-8", "pmcid": "PMC7577860", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID30980041", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Patient-derived neurons showed distinct mutation-specific Aβ processing signatures with raised Aβ42:40.", "what_it_does_not_show": "Cellular secretion signatures do not demonstrate organismal degeneration or a single uniform familial mechanism.", "confounders_present": [ "Cellular secretion signatures do not demonstrate organismal degeneration or a single uniform familial mechanism." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 22, "pmid": "26888304", "title": "Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database.", "citation": "Ringman JM, Monsell S, Ng DW et al. Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. Journal of neuropathology and experimental neurology. 2016.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26888304/", "url": "https://pubmed.ncbi.nlm.nih.gov/26888304/", "doi": "10.1093/jnen/nlv028", "pmcid": "PMC4934612", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID26888304", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Autosomal-dominant and sporadic autopsies differed in plaque, tau and vascular burden, with mutation-location heterogeneity.", "what_it_does_not_show": "Terminal pathology differences do not identify causal initiation or validate identical mechanisms across scopes.", "confounders_present": [ "Terminal pathology differences do not identify causal initiation or validate identical mechanisms across scopes." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 23, "pmid": "28533411", "title": "Bidirectional regulation of Aβ levels by Presenilin 1.", "citation": "Bustos V, Pulina MV, Kelahmetoglu Y et al. Bidirectional regulation of Aβ levels by Presenilin 1. Proceedings of the National Academy of Sciences of the United States of America. 2017.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/28533411/", "url": "https://pubmed.ncbi.nlm.nih.gov/28533411/", "doi": "10.1073/pnas.1705235114", "pmcid": "PMC5502639", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID28533411", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Presenilin phosphorylation altered Aβ through βCTF degradation and autophagy as well as catalytic processing.", "what_it_does_not_show": "Amyloid-marker effects alone do not establish clinical primacy; precursor-fragment mechanisms remain alternatives.", "confounders_present": [ "Amyloid-marker effects alone do not establish clinical primacy; precursor-fragment mechanisms remain alternatives." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 24, "pmid": "39613768", "title": "Altered expression of Presenilin2 impacts endolysosomal homeostasis and synapse function in Alzheimer's disease-relevant brain circuits.", "citation": "Perdok A, Van Acker ZP, Vrancx C et al. Altered expression of Presenilin2 impacts endolysosomal homeostasis and synapse function in Alzheimer's disease-relevant brain circuits. Nature communications. 2024.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39613768/", "url": "https://pubmed.ncbi.nlm.nih.gov/39613768/", "doi": "10.1038/s41467-024-54777-y", "pmcid": "PMC11607342", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID39613768", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3", "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "PSEN2 loss or mutation altered endolysosomal and synaptic physiology in female APP knock-in mice.", "what_it_does_not_show": "Sex/model restriction and non-Aβ presenilin functions prevent attributing all dysfunction to extracellular amyloid.", "confounders_present": [ "Sex/model restriction and non-Aβ presenilin functions prevent attributing all dysfunction to extracellular amyloid." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 25, "pmid": "33865446", "title": "A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.", "citation": "Swanson CJ, Zhang Y, Dhadda S et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer's research & therapy. 2021.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33865446/", "url": "https://pubmed.ncbi.nlm.nih.gov/33865446/", "doi": "10.1186/s13195-021-00813-8", "pmcid": "PMC8053280", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID35598024" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT01767311", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Phase-2 lecanemab missed its primary probability threshold but favored prespecified later clinical/biomarker comparisons.", "what_it_does_not_show": "The positive later analyses must not replace the negative primary; an erratum is linked and not separately counted.", "confounders_present": [ "The positive later analyses must not replace the negative primary; an erratum is linked and not separately counted." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 26, "pmid": "41330788", "title": "Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension.", "citation": "Zimmer JA, Sims JR, Evans CD et al. Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension. The journal of prevention of Alzheimer's disease. 2026.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41330788/", "url": "https://pubmed.ncbi.nlm.nih.gov/41330788/", "doi": "10.1016/j.tjpad.2025.100446", "pmcid": "PMC12869028", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT04437511", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Donanemab long-term extension reported sustained early-start advantage and slowing versus a weighted external cohort.", "what_it_does_not_show": "Extension completers and external ADNI comparisons are not a new long-duration concurrent placebo experiment.", "confounders_present": [ "Extension completers and external ADNI comparisons are not a new long-duration concurrent placebo experiment." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 27, "pmid": "41355080", "title": "Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study.", "citation": "van Dyck CH, Sperling R, Johnson K et al. Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41355080/", "url": "https://pubmed.ncbi.nlm.nih.gov/41355080/", "doi": "10.1002/alz.70905", "pmcid": "PMC12682705", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT03887455", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Clarity AD's open-label extension reported maintained early/delayed-start separation and favorable longer-term outcomes.", "what_it_does_not_show": "Open-label, selected continuation and subgroup analyses do not establish universal prevention or independent causal replication.", "confounders_present": [ "Open-label, selected continuation and subgroup analyses do not establish universal prevention or independent causal replication." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 28, "pmid": "40172303", "title": "Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction.", "citation": "Wang H, Serap Monkul Nery E, Ardayfio P et al. Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40172303/", "url": "https://pubmed.ncbi.nlm.nih.gov/40172303/", "doi": "10.1002/alz.70062", "pmcid": "PMC11963282", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "ErratumIn: PMID40775664" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID40172303", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Modified donanemab titration lowered ARIA risk while retaining comparable amyloid reduction.", "what_it_does_not_show": "The safety/engagement endpoint does not establish superior clinical efficacy; linked erratum impact on fine details remains unexamined.", "confounders_present": [ "The safety/engagement endpoint does not establish superior clinical efficacy; linked erratum impact on fine details remains unexamined." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 29, "pmid": "36544184", "title": "Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.", "citation": "McDade E, Cummings JL, Dhadda S et al. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimer's research & therapy. 2022.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36544184/", "url": "https://pubmed.ncbi.nlm.nih.gov/36544184/", "doi": "10.1186/s13195-022-01124-2", "pmcid": "PMC9768996", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT01767311", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "Study-201 follow-up found retained clinical separation during a treatment gap while plasma markers returned sooner than plaque PET.", "what_it_does_not_show": "The same cohort, nonrandomized gap/extension and differing randomized/treated denominators limit causal withdrawal or mediation claims.", "confounders_present": [ "The same cohort, nonrandomized gap/extension and differing randomized/treated denominators limit causal withdrawal or mediation claims." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 30, "pmid": "40063015", "title": "Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials.", "citation": "Zimmer JA, Ardayfio P, Wang H et al. Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials. JAMA neurology. 2025.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40063015/", "url": "https://pubmed.ncbi.nlm.nih.gov/40063015/", "doi": "10.1001/jamaneurol.2025.0065", "pmcid": "PMC11894547", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "TRAILBLAZER-ALZ+ALZ2+addendum", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "Donanemab secondary safety analyses documented ARIA and baseline risk associations.", "what_it_does_not_show": "Pooled trial/addendum specimens are reused; observational risk associations do not identify ARIA as the efficacy mediator.", "confounders_present": [ "Pooled trial/addendum specimens are reused; observational risk associations do not identify ARIA as the efficacy mediator." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 31, "pmid": "33253354", "title": "BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain.", "citation": "Sur C, Kost J, Scott D et al. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. Brain : a journal of neurology. 2020.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33253354/", "url": "https://pubmed.ncbi.nlm.nih.gov/33253354/", "doi": "10.1093/brain/awaa332", "pmcid": "PMC8453290", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT01739348", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "EPOCH exploratory imaging found rapid nonprogressive verubecestat-associated regional volume loss without a matching NfL rise.", "what_it_does_not_show": "MRI volume change is not automatically progressive neuronal death or selective loss of protective amyloid function.", "confounders_present": [ "MRI volume change is not automatically progressive neuronal death or selective loss of protective amyloid function." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 32, "pmid": "33049114", "title": "Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.", "citation": "Wessels AM, Lines C, Stern RA et al. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2020.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33049114/", "url": "https://pubmed.ncbi.nlm.nih.gov/33049114/", "doi": "10.1002/alz.12164", "pmcid": "", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "APECS+AMARANTH", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC5" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "contradicts", "what_it_shows": "APECS and AMARANTH secondary tests showed several worsened domains and improved verbal fluency with BACE inhibitors.", "what_it_does_not_show": "Mixed cognitive tasks and reused trial data do not form a new mechanistic line or a general beneficial aging effect.", "confounders_present": [ "Mixed cognitive tasks and reused trial data do not form a new mechanistic line or a general beneficial aging effect." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 33, "pmid": "40120616", "title": "Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial.", "citation": "Bateman RJ, Li Y, McDade EM et al. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. The Lancet. Neurology. 2025.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40120616/", "url": "https://pubmed.ncbi.nlm.nih.gov/40120616/", "doi": "10.1016/S1474-4422(25)00024-9", "pmcid": "PMC12042767", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "UpdateOf: PMID39974075", "ErratumIn: PMID40651485" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "DIAN-TU-001+OLE", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status record; selected primary-body sections: S10, S12, S17, S19. No full-paper or supplement audit.", "relates_to_subclaims": [ "SC4", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "supports", "what_it_shows": "DIAN gantenerumab extension achieved substantial plaque removal and suggested possible clinical delay after long exposure.", "what_it_does_not_show": "The final primary was PET; main-control clinical confidence intervals included no effect, with an extended-control contrast favorable. OLE/external controls and linked correction constrain proof.", "confounders_present": [ "The final primary was PET; main-control clinical confidence intervals included no effect, with an extended-control contrast favorable. OLE/external controls and linked correction constrain proof." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 34, "pmid": "33068398", "title": "Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease.", "citation": "Mattsson-Carlgren N, Janelidze S, Palmqvist S et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain : a journal of neurology. 2020.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33068398/", "url": "https://pubmed.ncbi.nlm.nih.gov/33068398/", "doi": "10.1093/brain/awaa286", "pmcid": "PMC7719022", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID33068398", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Longitudinal p-tau217 rose in amyloid-positive preclinical/prodromal groups and correlated with decline.", "what_it_does_not_show": "Temporal marker coupling does not selectively manipulate amyloid or establish tau's first origin.", "confounders_present": [ "Temporal marker coupling does not selectively manipulate amyloid or establish tau's first origin." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 35, "pmid": "39841807", "title": "Amyloid-associated hyperconnectivity drives tau spread across connected brain regions in Alzheimer's disease.", "citation": "Roemer-Cassiano SN, Wagner F, Evangelista L et al. Amyloid-associated hyperconnectivity drives tau spread across connected brain regions in Alzheimer's disease. Science translational medicine. 2025.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39841807/", "url": "https://pubmed.ncbi.nlm.nih.gov/39841807/", "doi": "10.1126/scitranslmed.adp2564", "pmcid": "", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID39841807", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Longitudinal cohorts associated amyloid-related hyperconnectivity with later tau accumulation.", "what_it_does_not_show": "Statistical mediation and replicated association are not a causal intervention on connectivity or amyloid.", "confounders_present": [ "Statistical mediation and replicated association are not a causal intervention on connectivity or amyloid." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 36, "pmid": "34259835", "title": "Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease.", "citation": "Pereira JB, Janelidze S, Smith R et al. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Brain : a journal of neurology. 2021.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34259835/", "url": "https://pubmed.ncbi.nlm.nih.gov/34259835/", "doi": "10.1093/brain/awab223", "pmcid": "PMC8677538", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID34259835", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Plasma GFAP associated with amyloid burden and longitudinal change after accounting for tau.", "what_it_does_not_show": "A glial biomarker and observational mediation do not establish inflammation's causal direction.", "confounders_present": [ "A glial biomarker and observational mediation do not establish inflammation's causal direction." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 37, "pmid": "32845545", "title": "Longitudinal atrophy in early Braak regions in preclinical Alzheimer's disease.", "citation": "Xie L, Wisse LEM, Das SR et al. Longitudinal atrophy in early Braak regions in preclinical Alzheimer's disease. Human brain mapping. 2020.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32845545/", "url": "https://pubmed.ncbi.nlm.nih.gov/32845545/", "doi": "10.1002/hbm.25151", "pmcid": "PMC7555086", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID32845545", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Preclinical medial-temporal atrophy was elevated in participants with concomitant tau, not the tau-negative group.", "what_it_does_not_show": "Baseline strata and imaging outcomes are prognostic evidence rather than tau necessity or amyloid inertness.", "confounders_present": [ "Baseline strata and imaging outcomes are prognostic evidence rather than tau necessity or amyloid inertness." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 38, "pmid": "36745413", "title": "Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.", "citation": "Mattsson-Carlgren N, Salvadó G, Ashton NJ et al. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA neurology. 2023.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/36745413/", "url": "https://pubmed.ncbi.nlm.nih.gov/36745413/", "doi": "10.1001/jamaneurol.2022.5272", "pmcid": "PMC10087054", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID36745413", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Plasma p-tau217 predicted later cognitive decline in amyloid-positive participants across cohorts.", "what_it_does_not_show": "Prediction conditional on amyloid positivity does not determine the universal initiating mechanism.", "confounders_present": [ "Prediction conditional on amyloid positivity does not determine the universal initiating mechanism." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 39, "pmid": "33285015", "title": "Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease.", "citation": "Hall S, Janelidze S, Londos E et al. Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease. Movement disorders : official journal of the Movement Disorder Society. 2021.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/33285015/", "url": "https://pubmed.ncbi.nlm.nih.gov/33285015/", "doi": "10.1002/mds.28370", "pmcid": "PMC8048822", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID33285015", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Phospho-tau markers detected Alzheimer co-pathology in a Lewy-body dementia sample.", "what_it_does_not_show": "Cross-sectional biomarker overlap cannot establish which pathology caused each person's dementia.", "confounders_present": [ "Cross-sectional biomarker overlap cannot establish which pathology caused each person's dementia." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 40, "pmid": "25499535", "title": "The transitional association between β-amyloid pathology and regional brain atrophy.", "citation": "Insel PS, Mattsson N, Donohue MC et al. The transitional association between β-amyloid pathology and regional brain atrophy. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2015.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/25499535/", "url": "https://pubmed.ncbi.nlm.nih.gov/25499535/", "doi": "10.1016/j.jalz.2014.11.002", "pmcid": "PMC4461550", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID25499535", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Spline analyses found accelerated regional atrophy before conventional CSF Aβ-positivity thresholds.", "what_it_does_not_show": "Subthreshold Aβ and measurement sensitivity remain possible; a diagnostic threshold is not true molecular absence.", "confounders_present": [ "Subthreshold Aβ and measurement sensitivity remain possible; a diagnostic threshold is not true molecular absence." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 41, "pmid": "32456694", "title": "Partial reduction of amyloid β production by β-secretase inhibitors does not decrease synaptic transmission.", "citation": "Satir TM, Agholme L, Karlsson A et al. Partial reduction of amyloid β production by β-secretase inhibitors does not decrease synaptic transmission. Alzheimer's research & therapy. 2020.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32456694/", "url": "https://pubmed.ncbi.nlm.nih.gov/32456694/", "doi": "10.1186/s13195-020-00635-0", "pmcid": "PMC7251689", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID32456694", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC5" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "in vitro", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Partial BACE inhibition reduced Aβ without impairing transmission in cortical cultures, whereas stronger suppression impaired transmission.", "what_it_does_not_show": "This dose boundary is not a human therapeutic window or an isolated test of Aβ-specific synaptic requirements.", "confounders_present": [ "This dose boundary is not a human therapeutic window or an isolated test of Aβ-specific synaptic requirements." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 42, "pmid": "24728269", "title": "Single App knock-in mouse models of Alzheimer's disease.", "citation": "Saito T, Matsuba Y, Mihira N et al. Single App knock-in mouse models of Alzheimer's disease. Nature neuroscience. 2014.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/24728269/", "url": "https://pubmed.ncbi.nlm.nih.gov/24728269/", "doi": "10.1038/nn.3697", "pmcid": "", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID24728269", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Physiological-promoter APP knock-in mice developed age-dependent Aβ pathology, inflammation and memory impairment.", "what_it_does_not_show": "Humanized familial mutations remain a genotype model; eliminating overexpression does not make all sporadic disease equivalent.", "confounders_present": [ "Humanized familial mutations remain a genotype model; eliminating overexpression does not make all sporadic disease equivalent." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 43, "pmid": "17478722", "title": "Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model.", "citation": "Roberson ED, Scearce-Levie K, Palop JJ et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science (New York, N.Y.). 2007.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/17478722/", "url": "https://pubmed.ncbi.nlm.nih.gov/17478722/", "doi": "10.1126/science.1141736", "pmcid": "", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID17478722", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC2", "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Endogenous tau reduction prevented APP-transgenic behavioral deficits without lowering Aβ.", "what_it_does_not_show": "Tau dependency in this model does not prove tau is the earliest human initiator; transgenic Aβ exposure still limits scope.", "confounders_present": [ "Tau dependency in this model does not prove tau is the earliest human initiator; transgenic Aβ exposure still limits scope." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 44, "pmid": "18568035", "title": "Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.", "citation": "Shankar GM, Li S, Mehta TH et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nature medicine. 2008.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/18568035/", "url": "https://pubmed.ncbi.nlm.nih.gov/18568035/", "doi": "10.1038/nm1782", "pmcid": "PMC2772133", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID18568035", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Human brain-derived Aβ dimers impaired rodent plasticity and memory; antibodies prevented selected effects and intact plaque cores were relatively inactive.", "what_it_does_not_show": "Forced extract administration demonstrates capacity, not endogenous human species necessity or propagation.", "confounders_present": [ "Forced extract administration demonstrates capacity, not endogenous human species necessity or propagation." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 45, "pmid": "39218977", "title": "Blockade of STING activation alleviates microglial dysfunction and a broad spectrum of Alzheimer's disease pathologies.", "citation": "Chung S, Jeong JH, Park JC et al. Blockade of STING activation alleviates microglial dysfunction and a broad spectrum of Alzheimer's disease pathologies. Experimental & molecular medicine. 2024.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39218977/", "url": "https://pubmed.ncbi.nlm.nih.gov/39218977/", "doi": "10.1038/s12276-024-01295-y", "pmcid": "PMC11447230", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID39218977", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "STING inhibition improved memory and multiple inflammatory/amyloid/tau features in a double-knock-in model.", "what_it_does_not_show": "Broad pathway effects do not identify a sole amyloid-primary or inflammation-primary initiator in sporadic humans.", "confounders_present": [ "Broad pathway effects do not identify a sole amyloid-primary or inflammation-primary initiator in sporadic humans." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 46, "pmid": "39042667", "title": "Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer's disease.", "citation": "Rajani RM, Ellingford R, Hellmuth M et al. Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer's disease. PLoS biology. 2024.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39042667/", "url": "https://pubmed.ncbi.nlm.nih.gov/39042667/", "doi": "10.1371/journal.pbio.3002727", "pmcid": "PMC11265669", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID39042667", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status record; selected primary-body sections: sec006, sec007, sec010, sec033. No full-paper or supplement audit.", "relates_to_subclaims": [ "SC1", "SC2", "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Strong", "system": "animal model", "decisive_perturbation": true, "endogenous": true, "direction": "supports", "what_it_shows": "Inducible oligodendrocyte BACE1 deletion reduced plaque burden and restored early neuronal firing in APP knock-in mice; Aβ-depleted conditioned medium lost acute hyperactivity effects.", "what_it_does_not_show": "BACE1 is pleiotropic, exposure began in young mice, and neuronal firing is not human clinical progression; injected medium is a separate forced sufficiency test.", "confounders_present": [ "BACE1 is pleiotropic, exposure began in young mice, and neuronal firing is not human clinical progression; injected medium is a separate forced sufficiency test." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 47, "pmid": "27258414", "title": "Non-Fibrillar Oligomeric Amyloid-β within Synapses.", "citation": "Pickett EK, Koffie RM, Wegmann S et al. Non-Fibrillar Oligomeric Amyloid-β within Synapses. Journal of Alzheimer's disease : JAD. 2016.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/27258414/", "url": "https://pubmed.ncbi.nlm.nih.gov/27258414/", "doi": "10.3233/JAD-160007", "pmcid": "", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID27258414", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC2" ], "favors_models": [ "M1" ], "evidence_class": "Weak", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Several high-resolution imaging assays localized oligomeric Aβ inside synapses of a plaque-bearing model.", "what_it_does_not_show": "Localization and agreement between imaging modalities do not establish synaptic species necessity.", "confounders_present": [ "Localization and agreement between imaging modalities do not establish synaptic species necessity." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 48, "pmid": "37907591", "title": "Mitochondrial hypermetabolism precedes impaired autophagy and synaptic disorganization in App knock-in Alzheimer mouse models.", "citation": "Naia L, Shimozawa M, Bereczki E et al. Mitochondrial hypermetabolism precedes impaired autophagy and synaptic disorganization in App knock-in Alzheimer mouse models. Molecular psychiatry. 2023.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/37907591/", "url": "https://pubmed.ncbi.nlm.nih.gov/37907591/", "doi": "10.1038/s41380-023-02289-4", "pmcid": "PMC10730401", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID37907591", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "APP knock-in time courses showed early mitochondrial hypermetabolism and later synaptic/autophagy abnormalities.", "what_it_does_not_show": "Model temporal order does not isolate the causal mediator or establish a universal human sequence.", "confounders_present": [ "Model temporal order does not isolate the causal mediator or establish a universal human sequence." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 49, "pmid": "41529684", "title": "Angiopoietin-2 aggravates Alzheimer's disease by promoting blood-brain barrier dysfunction and neuroinflammation.", "citation": "Lee E, Kim S, Zhu CL et al. Angiopoietin-2 aggravates Alzheimer's disease by promoting blood-brain barrier dysfunction and neuroinflammation. Cell reports. 2026.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/41529684/", "url": "https://pubmed.ncbi.nlm.nih.gov/41529684/", "doi": "10.1016/j.celrep.2025.116621", "pmcid": "PMC13058827", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID41529684", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Endothelial Angpt2 deletion lowered amyloid in 5xFAD; vascular and inflammatory pathways accompanied behavioral abnormalities.", "what_it_does_not_show": "Overexpression and knockout contrasts have different inferential strength; 5xFAD and vascular pleiotropy limit sporadic-human initiation claims.", "confounders_present": [ "Overexpression and knockout contrasts have different inferential strength; 5xFAD and vascular pleiotropy limit sporadic-human initiation claims." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 50, "pmid": "40830489", "title": "Early intervention anti-Aβ immunotherapy attenuates microglial activation without inducing exhaustion at residual plaques.", "citation": "de Weerd L, Hummel S, Müller SA et al. Early intervention anti-Aβ immunotherapy attenuates microglial activation without inducing exhaustion at residual plaques. Molecular neurodegeneration. 2025.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40830489/", "url": "https://pubmed.ncbi.nlm.nih.gov/40830489/", "doi": "10.1186/s13024-025-00878-1", "pmcid": "PMC12366171", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID40830489", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "animal model", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "Early anti-Aβ treatment in APP-SAA knock-in mice reduced plaque and broad disease-associated glial signals, with active glia at residual plaques.", "what_it_does_not_show": "The reported markers do not by themselves demonstrate preserved cognition, mediator necessity or complete disease prevention.", "confounders_present": [ "The reported markers do not by themselves demonstrate preserved cognition, mediator necessity or complete disease prevention." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 51, "pmid": "26938442", "title": "PET Imaging of Tau Deposition in the Aging Human Brain.", "citation": "Schöll M, Lockhart SN, Schonhaut DR et al. PET Imaging of Tau Deposition in the Aging Human Brain. Neuron. 2016.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/26938442/", "url": "https://pubmed.ncbi.nlm.nih.gov/26938442/", "doi": "10.1016/j.neuron.2016.01.028", "pmcid": "PMC4779187", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID26938442", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC3" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "Medial-temporal tau occurred with aging, while wider cortical tau was associated with amyloid and global decline.", "what_it_does_not_show": "Cross-sectional PET supports stage distinctions but cannot prove amyloid-free tau initiates AD or amyloid causes its expansion.", "confounders_present": [ "Cross-sectional PET supports stage distinctions but cannot prove amyloid-free tau initiates AD or amyloid causes its expansion." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 52, "pmid": "34155411", "title": "A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.", "citation": "Salloway S, Farlow M, McDade E et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nature medicine. 2021.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/34155411/", "url": "https://pubmed.ncbi.nlm.nih.gov/34155411/", "doi": "10.1038/s41591-021-01369-8", "pmcid": "PMC8988051", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "DIAN-TU-001", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status record; selected primary-body sections: S3, S4, S8, S9. No full-paper or supplement audit.", "relates_to_subclaims": [ "SC3", "SC4", "SC5" ], "favors_models": [ "M5" ], "evidence_class": "Strong", "system": "human interventional", "decisive_perturbation": true, "endogenous": true, "direction": "null", "what_it_shows": "DIAN randomized antibodies engaged targets without clinical benefit; gantenerumab moved tau and NfL markers.", "what_it_does_not_show": "The primary disease model did not converge, but sensitivity analyses agreed; late dose escalation and no asymptomatic decline limit prevention inference.", "confounders_present": [ "The primary disease model did not converge, but sensitivity analyses agreed; late dose escalation and no asymptomatic decline limit prevention inference." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 53, "pmid": "22784036", "title": "Clinical and biomarker changes in dominantly inherited Alzheimer's disease.", "citation": "Bateman RJ, Xiong C, Benzinger TL et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. The New England journal of medicine. 2012.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/22784036/", "url": "https://pubmed.ncbi.nlm.nih.gov/22784036/", "doi": "10.1056/NEJMoa1202753", "pmcid": "PMC3474597", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "ErratumIn: N Engl J Med 2012;367(8):780 (erratum notice has no PMID)" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID22784036", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC3", "SC4" ], "favors_models": [ "M1" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "supports", "what_it_shows": "DIAN baseline cross-sectional data inferred biomarker changes decades before expected symptoms.", "what_it_does_not_show": "A prospective cohort label does not turn this baseline analysis into observed within-person chronology; familial scope and an erratum are retained.", "confounders_present": [ "A prospective cohort label does not turn this baseline analysis into observed within-person chronology; familial scope and an erratum are retained." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 54, "pmid": "32376954", "title": "APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline.", "citation": "Montagne A, Nation DA, Sagare AP et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/32376954/", "url": "https://pubmed.ncbi.nlm.nih.gov/32376954/", "doi": "10.1038/s41586-020-2247-3", "pmcid": "PMC7250000", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID32376954", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC4" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "APOE4-associated BBB injury predicted decline after accounting for measured amyloid and tau.", "what_it_does_not_show": "This human prediction is not a vascular intervention or proof that every case is vascular-primary; pathology measurements are imperfect.", "confounders_present": [ "This human prediction is not a vascular intervention or proof that every case is vascular-primary; pathology measurements are imperfect." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 55, "pmid": "40459787", "title": "Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease.", "citation": "Chen CD, Franklin EE, Li Y et al. Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease. Acta neuropathologica. 2025.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/40459787/", "url": "https://pubmed.ncbi.nlm.nih.gov/40459787/", "doi": "10.1007/s00401-025-02890-7", "pmcid": "PMC12133910", "tier": "A", "source_tier": "A", "kind": "rct", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "DIAN-TU-001-autopsy-subset", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3", "SC5" ], "favors_models": [ "M5" ], "evidence_class": "Moderate", "system": "human interventional", "decisive_perturbation": false, "endogenous": true, "direction": "null", "what_it_shows": "Small selected DIAN autopsies showed dose-related gantenerumab plaque reduction without detectable tau/glial differences.", "what_it_does_not_show": "Nonrandom death/tissue selection and small groups constrain null downstream inference; this is reused DIAN evidence.", "confounders_present": [ "Nonrandom death/tissue selection and small groups constrain null downstream inference; this is reused DIAN evidence." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } }, { "n": 56, "pmid": "39930140", "title": "Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia.", "citation": "Llibre-Guerra JJ, Fernandez MV, Joseph-Mathurin N et al. Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia. Nature medicine. 2025.", "source_pointer": "https://pubmed.ncbi.nlm.nih.gov/39930140/", "url": "https://pubmed.ncbi.nlm.nih.gov/39930140/", "doi": "10.1038/s41591-025-03494-0", "pmcid": "PMC12024232", "tier": "A", "source_tier": "A", "kind": "primary", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID39930140", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "relates_to_subclaims": [ "SC1", "SC3", "SC4" ], "favors_models": [ "M5" ], "evidence_class": "Weak", "system": "human observational", "decisive_perturbation": false, "endogenous": false, "direction": "contradicts", "what_it_shows": "A longitudinal PSEN2 mutation-carrier case remained clinically resilient with restricted tau pathology.", "what_it_does_not_show": "A single case and candidate genetic/environmental explanations do not establish a protective mechanism or population frequency.", "confounders_present": [ "A single case and candidate genetic/environmental explanations do not establish a protective mechanism or population frequency." ], "verification": "verified", "verification_note": "Bounded result and limit checked against the actual access described; verified attribution is not proof of the hypothesis.", "citation_context": { "retrieved": false, "supporting_count": 0, "mentioning_count": 0, "contrasting_count": 0, "notable_contrasting_statements": [] } } ], "verification_summary": { "load_bearing_claims_checked": 63, "verified": 63, "unverified": 0, "contradicted": 0, "note": "All result/limit and subclaim cards are linked to examined primary access. Verified attribution is separate from completeness of full-text access and truth of the hypothesis." }, "factual_issues_found": [], "cap_rules_applied": [ { "subclaim_id": "SC1", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Maximum if mechanism is biologically plausible, supported by in vitro or simplified animal paradigms, but no disease-relevant necessity is shown in vivo.", "specific_trigger": "Plaque-targeting treatment changes early clinical trajectories, but a primary plaque-specific initiation mechanism is not isolated across AD. Plaques, soluble aggregates and immune clearance are not interchangeable mediators. Narrow causal support does not isolate full primacy/species/generalization.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC2", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Maximum if mechanism is biologically plausible, supported by in vitro or simplified animal paradigms, but no disease-relevant necessity is shown in vivo.", "specific_trigger": "Human extracts and selective model manipulations support soluble Aβ toxicity. BACE1 suppression is not oligomer-selective, and human CSF oligomer engagement has not isolated oligomer-specific clinical mediation. Defined mouse hyperactivity causality is retained separately at Ε. Narrow causal support does not isolate full primacy/species/generalization.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC3", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Maximum if mechanism is biologically plausible, supported by in vitro or simplified animal paradigms, but no disease-relevant necessity is shown in vivo.", "specific_trigger": "Amyloid can facilitate model injury and modulate tau markers; wider tau spread associates with amyloid in people. Early medial-temporal tau, human resilience, regional/null downstream responses and absent selective human mediation limit universal temporal primacy. Narrow causal support does not isolate full primacy/species/generalization.", "resulting_ceiling": "Γ" }, { "subclaim_id": "SC4", "cap": "Γ", "cap_source": "rubric", "triggered": true, "trigger_text_quoted": "Maximum if mechanism is biologically plausible, supported by in vitro or simplified animal paradigms, but no disease-relevant necessity is shown in vivo.", "specific_trigger": "Lifelong APP processing instruments and early-AD randomized clinical effects establish more than association, but neither proves that the full familial primary-initiation cascade explains sporadic disease across stages. This is the scope-matched gate. Narrow causal support does not isolate full primacy/species/generalization.", "resulting_ceiling": "Γ" } ], "cap_precedence_resolutions": [ { "collision": "Model causality versus broader human primacy inference", "subclaim_scope_cap_binds_on": "Universal human primacy, species necessity and familial-to-sporadic generalization", "subclaim_scope_threshold_binds_on": "Actual conditional-knockout/model and early symptomatic randomized clinical outcomes", "resolution": "A perturbation crosses a threshold within the system it was actually run in; broad inference requires its own evidence. Human intervention/genetics are assessed as a set rather than re-capped as pure association.", "note": "The positive SC5 and defined mouse results are not erased by the nominal Γ assessment." } ], "boundary_check_BGD": [ { "subclaim_id": "SC1", "field_valid_perturbation_quote": "\n- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo\n- Selective pathway inhibition that changes onset/progression while preserving broader viability\n- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated", "qualifying_evidence_present": "unclear", "qualifying_evidence_citation": "PMID36449413, PMID37459141, PMID37966285, PMID22801501, PMID38899694, PMID39042667", "gamma_hard_rules_triggered": [ "In vitro aggregation alone — constrains isolated assays, not the assembled clinical/genetic set.", "In vitro seeding alone — not sole evidence.", "Droplet aging in vitro — not invoked.", "Organoid toxicity without organismal follow-through — not the complete evidence base.", "Exogenous seeding models alone — not sole evidence; injected extract inference remains bounded." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Narrow positive results are retained; no positive perturbation identifies the complete nominal primary-initiation inference for this subclaim.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC2", "field_valid_perturbation_quote": "\n- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo\n- Selective pathway inhibition that changes onset/progression while preserving broader viability\n- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated", "qualifying_evidence_present": "unclear", "qualifying_evidence_citation": "PMID17478722, PMID39042667", "gamma_hard_rules_triggered": [ "In vitro aggregation alone — constrains isolated assays, not the assembled clinical/genetic set.", "In vitro seeding alone — not sole evidence.", "Droplet aging in vitro — not invoked.", "Organoid toxicity without organismal follow-through — not the complete evidence base.", "Exogenous seeding models alone — not sole evidence; injected extract inference remains bounded." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Narrow positive results are retained; no positive perturbation identifies the complete nominal primary-initiation inference for this subclaim.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC3", "field_valid_perturbation_quote": "\n- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo\n- Selective pathway inhibition that changes onset/progression while preserving broader viability\n- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated", "qualifying_evidence_present": "unclear", "qualifying_evidence_citation": "PMID37966285, PMID38899694, PMID17478722, PMID39042667, PMID34155411", "gamma_hard_rules_triggered": [ "In vitro aggregation alone — constrains isolated assays, not the assembled clinical/genetic set.", "In vitro seeding alone — not sole evidence.", "Droplet aging in vitro — not invoked.", "Organoid toxicity without organismal follow-through — not the complete evidence base.", "Exogenous seeding models alone — not sole evidence; injected extract inference remains bounded." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Narrow positive results are retained; no positive perturbation identifies the complete nominal primary-initiation inference for this subclaim.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC4", "field_valid_perturbation_quote": "\n- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo\n- Selective pathway inhibition that changes onset/progression while preserving broader viability\n- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated", "qualifying_evidence_present": "unclear", "qualifying_evidence_citation": "PMID36449413, PMID37459141, PMID37458272, PMID30970186, PMID22801501, PMID41579901, PMID38899694, PMID34155411", "gamma_hard_rules_triggered": [ "In vitro aggregation alone — constrains isolated assays, not the assembled clinical/genetic set.", "In vitro seeding alone — not sole evidence.", "Droplet aging in vitro — not invoked.", "Organoid toxicity without organismal follow-through — not the complete evidence base.", "Exogenous seeding models alone — not sole evidence; injected extract inference remains bounded." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "no", "perturbation_result_note": "Narrow positive results are retained; no positive perturbation identifies the complete nominal primary-initiation inference for this subclaim.", "ceiling_from_boundary_check": "Γ" }, { "subclaim_id": "SC5", "field_valid_perturbation_quote": "\n- Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo\n- Selective pathway inhibition that changes onset/progression while preserving broader viability\n- Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated", "qualifying_evidence_present": "yes", "qualifying_evidence_citation": "PMID36449413, PMID37459141, PMID37966285, PMID37458272, PMID30970186, PMID41579901, PMID34155411", "gamma_hard_rules_triggered": [ "In vitro aggregation alone — constrains isolated assays, not the assembled clinical/genetic set.", "In vitro seeding alone — not sole evidence.", "Droplet aging in vitro — not invoked.", "Organoid toxicity without organismal follow-through — not the complete evidence base.", "Exogenous seeding models alone — not sole evidence; injected extract inference remains bounded." ], "disease_phenotype_relevance": "yes", "perturbation_result_positive": "yes", "perturbation_result_note": "Lecanemab and donanemab favor clinical cognition/function, not only biomarkers.", "ceiling_from_boundary_check": "Δ or higher" } ], "thresholds_tested": [ { "subclaim_id": "SC1", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "no", "supporting_evidence": [ "[1] Lecanemab slowed cognitive and functional decline in amyloid-confirmed early AD, with adverse events.", "[2] Donanemab favored clinical outcomes in early symptomatic amyloid/tau-positive AD.", "[3] Gantenerumab reduced plaque and fluid tau markers without significant primary clinical slowing in either GRADUATE trial.", "[15] APP A673T was associated with protection and reduced amyloidogenic processing in functional assays.", "[19] APOE3 Christchurch heterozygotes in the PSEN1 kindred had delayed impairment; selected autopsies showed substantial plaque with limited tau.", "[46] Inducible oligodendrocyte BACE1 deletion reduced plaque burden and restored early neuronal firing in APP knock-in mice; Aβ-depleted conditioned medium lost acute hyperactivity effects." ], "what_would_cross_it": "Clinical trajectory following selective plaque perturbation with functional endpoints, specificity and prospectively defined scope." }, { "subclaim_id": "SC2", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "no", "supporting_evidence": [ "[43] Endogenous tau reduction prevented APP-transgenic behavioral deficits without lowering Aβ.", "[46] Inducible oligodendrocyte BACE1 deletion reduced plaque burden and restored early neuronal firing in APP knock-in mice; Aβ-depleted conditioned medium lost acute hyperactivity effects." ], "what_would_cross_it": "Oligomer-selective depletion with plaque burden preserved with functional endpoints, specificity and prospectively defined scope." }, { "subclaim_id": "SC3", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "no", "supporting_evidence": [ "[3] Gantenerumab reduced plaque and fluid tau markers without significant primary clinical slowing in either GRADUATE trial.", "[19] APOE3 Christchurch heterozygotes in the PSEN1 kindred had delayed impairment; selected autopsies showed substantial plaque with limited tau.", "[43] Endogenous tau reduction prevented APP-transgenic behavioral deficits without lowering Aβ.", "[46] Inducible oligodendrocyte BACE1 deletion reduced plaque burden and restored early neuronal firing in APP knock-in mice; Aβ-depleted conditioned medium lost acute hyperactivity effects.", "[52] DIAN randomized antibodies engaged targets without clinical benefit; gantenerumab moved tau and NfL markers." ], "what_would_cross_it": "Aβ perturbation preventing or delaying tau and clinical injury with functional endpoints, specificity and prospectively defined scope." }, { "subclaim_id": "SC4", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "no", "supporting_evidence": [ "[1] Lecanemab slowed cognitive and functional decline in amyloid-confirmed early AD, with adverse events.", "[2] Donanemab favored clinical outcomes in early symptomatic amyloid/tau-positive AD.", "[5] Solanezumab did not slow preclinical cognitive decline; amyloid PET increased in both arms.", "[8] Prodromal verubecestat was ineffective and the higher dose worsened the primary clinical outcome.", "[15] APP A673T was associated with protection and reduced amyloidogenic processing in functional assays.", "[18] The completed Colombian crenezumab prevention trial found no significant benefit on either primary clinical endpoint and no clear plaque-removal effect.", "[19] APOE3 Christchurch heterozygotes in the PSEN1 kindred had delayed impairment; selected autopsies showed substantial plaque with limited tau.", "[52] DIAN randomized antibodies engaged targets without clinical benefit; gantenerumab moved tau and NfL markers." ], "what_would_cross_it": "Human genetics and clinical intervention separating contribution from initiation/primacy with functional endpoints, specificity and prospectively defined scope." }, { "subclaim_id": "SC5", "threshold": "Δ", "requirement_quoted": "Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.", "satisfied": "yes", "supporting_evidence": [ "[1] Lecanemab slowed cognitive and functional decline in amyloid-confirmed early AD, with adverse events.", "[2] Donanemab favored clinical outcomes in early symptomatic amyloid/tau-positive AD.", "[3] Gantenerumab reduced plaque and fluid tau markers without significant primary clinical slowing in either GRADUATE trial.", "[5] Solanezumab did not slow preclinical cognitive decline; amyloid PET increased in both arms.", "[8] Prodromal verubecestat was ineffective and the higher dose worsened the primary clinical outcome.", "[18] The completed Colombian crenezumab prevention trial found no significant benefit on either primary clinical endpoint and no clear plaque-removal effect.", "[52] DIAN randomized antibodies engaged targets without clinical benefit; gantenerumab moved tau and NfL markers." ], "what_would_cross_it": "" }, { "subclaim_id": "SC5", "threshold": "Ε", "requirement_quoted": "Requires causal support in a defined context, but with clear restriction by subtype, disease stage, model, or tissue.\n\nUse Ε when there is a real causal contribution, but generalization to the entire disease class fails.", "satisfied": "yes", "supporting_evidence": [ "[1] Lecanemab slowed cognitive and functional decline in amyloid-confirmed early AD, with adverse events.", "[2] Donanemab favored clinical outcomes in early symptomatic amyloid/tau-positive AD.", "[3] Gantenerumab reduced plaque and fluid tau markers without significant primary clinical slowing in either GRADUATE trial.", "[5] Solanezumab did not slow preclinical cognitive decline; amyloid PET increased in both arms.", "[8] Prodromal verubecestat was ineffective and the higher dose worsened the primary clinical outcome.", "[18] The completed Colombian crenezumab prevention trial found no significant benefit on either primary clinical endpoint and no clear plaque-removal effect.", "[52] DIAN randomized antibodies engaged targets without clinical benefit; gantenerumab moved tau and NfL markers." ], "what_would_cross_it": "" }, { "subclaim_id": "SC5", "threshold": "Ζ", "requirement_quoted": "Requires:\n- Multiple independent causal lines in vivo\n- Replication across at least two relevant systems\n- Narrowing of major alternative models", "satisfied": "no", "supporting_evidence": [ "[1] Lecanemab slowed cognitive and functional decline in amyloid-confirmed early AD, with adverse events.", "[2] Donanemab favored clinical outcomes in early symptomatic amyloid/tau-positive AD.", "[3] Gantenerumab reduced plaque and fluid tau markers without significant primary clinical slowing in either GRADUATE trial.", "[5] Solanezumab did not slow preclinical cognitive decline; amyloid PET increased in both arms.", "[8] Prodromal verubecestat was ineffective and the higher dose worsened the primary clinical outcome.", "[18] The completed Colombian crenezumab prevention trial found no significant benefit on either primary clinical endpoint and no clear plaque-removal effect.", "[52] DIAN randomized antibodies engaged targets without clinical benefit; gantenerumab moved tau and NfL markers." ], "what_would_cross_it": "Randomized clinical outcomes with target engagement with functional endpoints, specificity and prospectively defined scope." } ], "generalization_check": { "generalization_tested": "yes", "context_boundary_mapped": "yes", "internal_negative_controls": [ "Clinical positive and null contrasts across baseline stages and agents; APP family and BBB/tau heterogeneity are preserved." ], "note": "SC5 has mapped context/pharmacology limits; universal initiating primacy and selective oligomer necessity are not thereby established." }, "falsification_patterns_met": [ { "subclaim_id": "SC4", "pattern": "Subtype heterogeneity shows the mechanism is non-general but the hypothesis is framed as general", "evidence": "The source cards retain counterexamples and intervention nulls; these constrain the same generalization gap already used in the Γ assessment.", "downgrade_applied": false }, { "subclaim_id": "SC5", "pattern": "Blocking the proposed mechanism does not alter onset/progression in vivo", "evidence": "Negative agents and stages do not erase the separately positive lecanemab/donanemab contexts. Engagement/specificity limits forbid treating every null as total-mechanism blockade.", "downgrade_applied": false } ], "pitfalls_flagged": [ { "subclaim_id": "SC4", "pitfall": "6. Downstream effect treated as upstream driver", "where": "Clinical slowing is contribution, not automatic earliest initiation." }, { "subclaim_id": "SC4", "pitfall": "10. Mechanism conflation", "where": "Plaques, oligomers, BACE and precursor/presenilin functions are distinguished." }, { "subclaim_id": "SC4", "pitfall": "12. Temporal order inferred rather than demonstrated", "where": "The 2012 DIAN baseline analysis is cross-sectional, despite prospective study enrollment." }, { "subclaim_id": "SC4", "pitfall": "13. Therapeutic effect misread as mechanistic proof", "where": "Target engagement and clinical benefit do not isolate every mediator." }, { "subclaim_id": "SC4", "pitfall": "17. Negative field-valid perturbation read as a crossed threshold", "where": "Negative drug results do not count as positive Δ support." }, { "subclaim_id": "SC4", "pitfall": "21. A universal cap re-applied to a convergent evidence set", "where": "Human instruments and clinical evidence are evaluated together." }, { "subclaim_id": "SC4", "pitfall": "22. Scope fitted to the result", "where": "Baseline stage and genotype define contexts; responding patients do not define scope." } ], "causal_tally_audit": { "tally_claimed_by_document": 11, "tally_after_audit": 11, "items_rejected": [ "The tally includes decisive null/negative discriminators and is not a count of positive complete nominal tests.", "The complete universal sporadic primary-initiation cascade has zero positive selectively identifying tests in this bounded inventory.", "Secondary reports, genetic kindred overlap and repeated antibody agents are not separate independent causal lines." ] }, "steelman": { "case_one_rung_higher": "For Δ, lifelong protective APP processing variation, familial gene-dose instruments, endogenous mouse depletion and positive human clinical intervention form a compelling causal set. A charitable reading would treat this as proof of the primary upstream cascade in sporadic disease.", "case_one_rung_lower": "For Β, broad human initiation/primacy is still largely inferred from pathology chronology; prevention and BACE trials are null or harmful, and severe amyloid can coexist with delayed cognitive impairment.", "which_rejected": "Reject Δ for the exact primary-initiation gate: clinical contribution and APP processing risk are not selective identification of the full initiating cascade in sporadic AD. Reject Β for the mechanistic whole: verified intervention, functional depletion and genetic instruments are not mere co-occurrence. Γ does not downgrade the independently positive SC5.", "blocking_cap_threshold_or_missing_experiment": "Missing experiment: selective prospective identification of sporadic primary initiation, distinct from stage-specific clinical slowing. Randomize preclinical amyloid-positive participants to verified aggregate reduction with prospectively defined clinical follow-up, baseline tau/vascular stratification and blinded outcomes. Include a species-selective mediator contrast where feasible. Prevention of tau-linked injury and clinical onset would strengthen initiation; adequate sustained engagement with unchanged clinical onset would constrain it. Preserve non-Aβ APP/BACE functions and monitor harms." }, "final_score": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "56 primary reports examined; 4 selected partial-body examinations. Replication, heterogeneity, shared cohorts, specificity and incomplete correction-body access support Moderate confidence in this bounded adjudication.", "rests_on_non_peer_reviewed_work": false, "rationale": "Scope-matched SC4 returns Γ for primary initiation/generalization; SC5 separately returns Ε for early clinical contribution. Human genetics and clinical perturbations are considered together and are not re-capped as mere association. Their convergence supports bounded amyloid contribution, while sole/primary initiation and exact pathogenic-species mediation remain unresolved." }, "role_of_mechanism": { "classification": "reinforcing / stabilizing factor", "derivation_step_matched": "5", "derivation": "At sporadic disease scope, production solely by established disease is not demonstrated (step 1), and intervention-sensitive clinical contribution rejects co-occurrence alone (step 2). Removal, initiation and rate limitation are not jointly established (step 3), nor universal necessity (step 4). Amyloid amplifies or maintains injury in the observed early-disease contexts, so step 5 is the first defensible match. Familial APP pathogenicity is stronger and separately scoped.", "tournament_used_as_tiebreaker": false, "note": "Derived from causal direction, not tournament rank." }, "extended_scoring_MSD": { "momentum": { "value": "Decisive work underway", "artifact": "TRAILBLAZER-ALZ 3 (NCT05026866): preclinical donanemab prevention; screening/baseline report PMID40955720 is a discovery lead and is not counted as a completed outcome trial.", "justification": "A named prospective programme addresses the next causal boundary." }, "stability": { "value": "Uncertain", "trigger": "The named preclinical plaque-removal prevention trial could strengthen or weaken amyloid-initiation inference depending on clinical outcomes and verified target engagement. Neither direction is presumed.", "justification": "An identifiable result could move initiation inference in either direction; no outcome is assumed." }, "divergence": { "implied_level": null, "implied_level_basis": "The ranked document and mechanistic discovery results include conflicting field framings; no single field-implied primary-initiation level is defensible.", "assessed_level": "Γ", "gap_in_rungs": null, "value": "Contested", "justification": "No manufactured consensus or arithmetic gap." }, "calibration_note": "M/S/D never modify HSEF level or confidence." }, "change_record": { "applies": false, "prior_level": "No prior HSEF letter consulted; ranking categorical verdict visible", "prior_confidence": null, "prior_source": null, "derived_before_consulting_prior": false, "new_level": "Γ", "direction": "newly assigned", "what_moved_it": "New evidence-bounded assessment; this run is not blinded.", "divergence_from_other_reviewers": null }, "proposed_decisive_experiments": [ { "name": "Prospective initiation and mediator test", "experiment": "Randomize preclinical amyloid-positive participants to verified aggregate reduction with prospectively defined clinical follow-up, baseline tau/vascular stratification and blinded outcomes. Include a species-selective mediator contrast where feasible. Prevention of tau-linked injury and clinical onset would strengthen initiation; adequate sustained engagement with unchanged clinical onset would constrain it. Preserve non-Aβ APP/BACE functions and monitor harms.", "readout": "Clinical onset/trajectory plus engagement and tau/vascular injury.", "critical_control": "Prespecified enrollment and follow-up; matched outcomes and substrate specificity.", "supporting_result": "Consistent prevention with target engagement and causal mediator separation.", "falsifying_result": "Adequate engagement without clinical prevention, or effect attributed to another mediator." } ], "knowledge_gaps": [ { "name": "Gap 1", "statement": "Selective human oligomer-versus-plaque clinical mediation remains unisolated.", "relevance": "Limits generalization or mechanistic identification." }, { "name": "Gap 2", "statement": "Preventive target engagement and clinical outcomes require a coherent prospective bridge.", "relevance": "Limits generalization or mechanistic identification." }, { "name": "Gap 3", "statement": "Familial, late-onset sporadic, tau-defined and vascular/mixed scopes need prospective stratification.", "relevance": "Limits generalization or mechanistic identification." }, { "name": "Gap 4", "statement": "Most of this bounded corpus was examined at complete-abstract/status depth, not full report/supplement depth; linked correction bodies remain incompletely examined.", "relevance": "Limits generalization or mechanistic identification." } ], "review_metadata": { "review_date": "2026-10-04", "reviewer": "Codex", "evidence_base_note": "56 examined primary reports; publication cutoff 2026-10-04. Bounded critical review, not exhaustive systematic search.", "literature_tools_available": true, "literature_tools_note": "Life Sciences Literature public PubMed/PMC, SciSpace, authenticated Consensus and primary-site web verification. Scite quota unavailable in preceding batch; no citation-context counts invented.", "skill_version": "5.3", "validator_run": "Archived validator run; receipt and logs accompany this pair.", "validator_warnings_addressed": "Claim-form warning is justified: the popularity-list topic is explicitly restated as a causal proposition. The steelman specifies the missing experiment.", "consensus_consistency_audit": "2026-10-09; supplementary provenance/source reconciliation; original grading retained; prior grades visible." }, "is_calibration_entry": { "value": false, "entry_role": "not_calibration", "blind_graded": null, "completed_blinded_calibration": false, "expected_band_sealed_at": "", "target_sha256": "", "target_authorship": "not applicable", "target_author_saw_review": null, "future_run_status": "not prepared", "unblinded_reason": "Popularity document categorical verdicts and index guidance were visible. No completed blinded calibration asserted." }, "upper_ladder_check": { "final_level_below_zeta": true, "equivalents_considered": [ { "kind": "mendelian_randomization", "available": false, "why_not_sufficient": "Human genetic instruments, clinical antibodies and off-treatment observations are retained. They identify contribution/processing risk, not complete sporadic primary initiation, species-selective necessity or fully randomized causal mediation. No deliberate human initiation trial is demanded." }, { "kind": "natural_experiment", "available": true, "why_not_sufficient": "Human genetic instruments, clinical antibodies and off-treatment observations are retained. They identify contribution/processing risk, not complete sporadic primary initiation, species-selective necessity or fully randomized causal mediation. No deliberate human initiation trial is demanded." }, { "kind": "dose_response_across_populations", "available": false, "why_not_sufficient": "Human genetic instruments, clinical antibodies and off-treatment observations are retained. They identify contribution/processing risk, not complete sporadic primary initiation, species-selective necessity or fully randomized causal mediation. No deliberate human initiation trial is demanded." }, { "kind": "withdrawal_rechallenge", "available": true, "why_not_sufficient": "Human genetic instruments, clinical antibodies and off-treatment observations are retained. They identify contribution/processing risk, not complete sporadic primary initiation, species-selective necessity or fully randomized causal mediation. No deliberate human initiation trial is demanded." }, { "kind": "therapeutic_perturbation_hard_endpoint", "available": true, "why_not_sufficient": "Human genetic instruments, clinical antibodies and off-treatment observations are retained. They identify contribution/processing risk, not complete sporadic primary initiation, species-selective necessity or fully randomized causal mediation. No deliberate human initiation trial is demanded." } ], "convergence_present": true, "cap_reapplied_to_convergent_set": false }, "provenance_header": { "sources_total": 56, "claims_total": 63, "claims_verified": 63, "claims_unverified": 0, "claims_contradicted": 0, "tier_a_sources": 56, "generated_by": "Codex; HSEF v5.3", "gate_passed": true }, "claims": [ { "id": "C1", "text": "Lecanemab slowed cognitive and functional decline in amyloid-confirmed early AD, with adverse events. Clinical slowing does not establish complete mediation, universal initiation, halt or reversal of disease.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4", "SC5" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C2", "text": "Donanemab favored clinical outcomes in early symptomatic amyloid/tau-positive AD. Both groups worsened; this is stage-specific contribution rather than proof of a sole initiator.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4", "SC5" ], "source_ns": [ 2 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C3", "text": "Gantenerumab reduced plaque and fluid tau markers without significant primary clinical slowing in either GRADUATE trial. Incomplete plaque removal and target/stage differences limit a universal null inference; tau PET was similar.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3", "SC5" ], "source_ns": [ 3 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C4", "text": "Aducanumab's EMERGE clinical comparison was positive and ENGAGE was null despite marker engagement in both. Discordance, early futility stopping and exposure differences prevent treating the pair as consistent clinical replication.", "carries_number": false, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 4 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C5", "text": "Solanezumab did not slow preclinical cognitive decline; amyloid PET increased in both arms. Monomer targeting and incomplete prevention of deposition do not test complete plaque eradication.", "carries_number": false, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 5 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C6", "text": "Solanezumab did not meet its mild-AD primary clinical endpoint. Hierarchical secondary outcomes were descriptive; this agent's null does not erase antibody-specific positives.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 6 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C7", "text": "Verubecestat did not improve cognitive or functional decline in mild-to-moderate AD and increased adverse events. BACE inhibition affects non-Aβ substrates and is not a selective experiment on pathological aggregates.", "carries_number": false, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 7 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C8", "text": "Prodromal verubecestat was ineffective and the higher dose worsened the primary clinical outcome. Early stopping, BACE substrate pleiotropy and drug harms prevent equating this with selective Aβ harm removal.", "carries_number": false, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 8 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C9", "text": "Atabecestat caused dose-related cognitive worsening with evidence of reversibility after withdrawal. A truncated hepatic-safety-stopped trial does not isolate the specific Aβ versus other BACE-dependent functions.", "carries_number": false, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 9 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C10", "text": "Lanabecestat failed to slow clinical decline in AMARANTH and DAYBREAK. Premature termination and substrate specificity constrain the mechanistic inference; a PET-sign erratum is attached.", "carries_number": false, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 10 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C11", "text": "Phase-2 donanemab favored its primary integrated clinical score; most secondary comparisons were mixed. This primary contrast is not the same as all participants in later post-hoc analyses, and tau change was small globally.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3", "SC5" ], "source_ns": [ 11 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C12", "text": "Post-hoc donanemab analyses linked clearance to regional tau slowing and clinical model effects in APOE4 carriers. Postrandomization associations and model forecasts are not randomized mediator manipulation or a new trial.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3", "SC5" ], "source_ns": [ 12 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C13", "text": "Crenezumab lowered measured CSF oligomer levels in phase-2 trial specimens. Fluid target engagement does not establish brain-species selective depletion or clinical efficacy.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 13 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C14", "text": "Two terminated global bapineuzumab trials were null for clinical outcomes and their examined biomarker contrasts. Dose, stage and absent biomarker movement limit claims that successful selective removal was clinically ineffective.", "carries_number": false, "load_bearing_for": [ "SC1", "SC5" ], "source_ns": [ 14 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C15", "text": "APP A673T was associated with protection and reduced amyloidogenic processing in functional assays. A rare lifelong processing variant is stronger than pathology co-occurrence but does not isolate every APP product or all sporadic cases.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 15 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C16", "text": "An APP missense variant segregated with early-onset familial AD in two unrelated families. The instrument concerns selected familial disease, not all late-onset sporadic initiation.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 16 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C17", "text": "APP-locus duplications occurred in families with early-onset AD and prominent cerebral amyloid angiopathy. Gene dosage affects the precursor and vascular/parenchymal biology, not exclusively plaque toxicity.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 17 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C18", "text": "The completed Colombian crenezumab prevention trial found no significant benefit on either primary clinical endpoint and no clear plaque-removal effect. It cannot be described as a successful plaque-clearance prevention test; limited engagement constrains interpretation.", "carries_number": false, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 18 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C19", "text": "APOE3 Christchurch heterozygotes in the PSEN1 kindred had delayed impairment; selected autopsies showed substantial plaque with limited tau. Related-kindred sampling, sparse imaging/autopsy and qualitative unquantified pathology do not prove amyloid is causally irrelevant.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3", "SC4" ], "source_ns": [ 19 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status record; selected primary-body sections: S7, S13, S14. No full-paper or supplement audit.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C20", "text": "Early-onset screening identified familial and de novo APP/presenilin variants, including apparently sporadic presentations. Apparently sporadic early-onset mutation carriers are not equivalent to general late-onset sporadic AD; some variant pathogenicity was unresolved.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 20 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C21", "text": "Patient-derived neurons showed distinct mutation-specific Aβ processing signatures with raised Aβ42:40. Cellular secretion signatures do not demonstrate organismal degeneration or a single uniform familial mechanism.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 21 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C22", "text": "Autosomal-dominant and sporadic autopsies differed in plaque, tau and vascular burden, with mutation-location heterogeneity. Terminal pathology differences do not identify causal initiation or validate identical mechanisms across scopes.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 22 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C23", "text": "Presenilin phosphorylation altered Aβ through βCTF degradation and autophagy as well as catalytic processing. Amyloid-marker effects alone do not establish clinical primacy; precursor-fragment mechanisms remain alternatives.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 23 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C24", "text": "PSEN2 loss or mutation altered endolysosomal and synaptic physiology in female APP knock-in mice. Sex/model restriction and non-Aβ presenilin functions prevent attributing all dysfunction to extracellular amyloid.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3", "SC4" ], "source_ns": [ 24 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C25", "text": "Phase-2 lecanemab missed its primary probability threshold but favored prespecified later clinical/biomarker comparisons. The positive later analyses must not replace the negative primary; an erratum is linked and not separately counted.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 25 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C26", "text": "Donanemab long-term extension reported sustained early-start advantage and slowing versus a weighted external cohort. Extension completers and external ADNI comparisons are not a new long-duration concurrent placebo experiment.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 26 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C27", "text": "Clarity AD's open-label extension reported maintained early/delayed-start separation and favorable longer-term outcomes. Open-label, selected continuation and subgroup analyses do not establish universal prevention or independent causal replication.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 27 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C28", "text": "Modified donanemab titration lowered ARIA risk while retaining comparable amyloid reduction. The safety/engagement endpoint does not establish superior clinical efficacy; linked erratum impact on fine details remains unexamined.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 28 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C29", "text": "Study-201 follow-up found retained clinical separation during a treatment gap while plasma markers returned sooner than plaque PET. The same cohort, nonrandomized gap/extension and differing randomized/treated denominators limit causal withdrawal or mediation claims.", "carries_number": false, "load_bearing_for": [ "SC3", "SC5" ], "source_ns": [ 29 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C30", "text": "Donanemab secondary safety analyses documented ARIA and baseline risk associations. Pooled trial/addendum specimens are reused; observational risk associations do not identify ARIA as the efficacy mediator.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 30 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C31", "text": "EPOCH exploratory imaging found rapid nonprogressive verubecestat-associated regional volume loss without a matching NfL rise. MRI volume change is not automatically progressive neuronal death or selective loss of protective amyloid function.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 31 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C32", "text": "APECS and AMARANTH secondary tests showed several worsened domains and improved verbal fluency with BACE inhibitors. Mixed cognitive tasks and reused trial data do not form a new mechanistic line or a general beneficial aging effect.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 32 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C33", "text": "DIAN gantenerumab extension achieved substantial plaque removal and suggested possible clinical delay after long exposure. The final primary was PET; main-control clinical confidence intervals included no effect, with an extended-control contrast favorable. OLE/external controls and linked correction constrain proof.", "carries_number": false, "load_bearing_for": [ "SC4", "SC5" ], "source_ns": [ 33 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status record; selected primary-body sections: S10, S12, S17, S19. No full-paper or supplement audit.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C34", "text": "Longitudinal p-tau217 rose in amyloid-positive preclinical/prodromal groups and correlated with decline. Temporal marker coupling does not selectively manipulate amyloid or establish tau's first origin.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 34 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C35", "text": "Longitudinal cohorts associated amyloid-related hyperconnectivity with later tau accumulation. Statistical mediation and replicated association are not a causal intervention on connectivity or amyloid.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 35 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C36", "text": "Plasma GFAP associated with amyloid burden and longitudinal change after accounting for tau. A glial biomarker and observational mediation do not establish inflammation's causal direction.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 36 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C37", "text": "Preclinical medial-temporal atrophy was elevated in participants with concomitant tau, not the tau-negative group. Baseline strata and imaging outcomes are prognostic evidence rather than tau necessity or amyloid inertness.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 37 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C38", "text": "Plasma p-tau217 predicted later cognitive decline in amyloid-positive participants across cohorts. Prediction conditional on amyloid positivity does not determine the universal initiating mechanism.", "carries_number": false, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 38 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C39", "text": "Phospho-tau markers detected Alzheimer co-pathology in a Lewy-body dementia sample. Cross-sectional biomarker overlap cannot establish which pathology caused each person's dementia.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 39 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C40", "text": "Spline analyses found accelerated regional atrophy before conventional CSF Aβ-positivity thresholds. Subthreshold Aβ and measurement sensitivity remain possible; a diagnostic threshold is not true molecular absence.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 40 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C41", "text": "Partial BACE inhibition reduced Aβ without impairing transmission in cortical cultures, whereas stronger suppression impaired transmission. This dose boundary is not a human therapeutic window or an isolated test of Aβ-specific synaptic requirements.", "carries_number": false, "load_bearing_for": [ "SC2", "SC5" ], "source_ns": [ 41 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C42", "text": "Physiological-promoter APP knock-in mice developed age-dependent Aβ pathology, inflammation and memory impairment. Humanized familial mutations remain a genotype model; eliminating overexpression does not make all sporadic disease equivalent.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 42 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C43", "text": "Endogenous tau reduction prevented APP-transgenic behavioral deficits without lowering Aβ. Tau dependency in this model does not prove tau is the earliest human initiator; transgenic Aβ exposure still limits scope.", "carries_number": false, "load_bearing_for": [ "SC2", "SC3" ], "source_ns": [ 43 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C44", "text": "Human brain-derived Aβ dimers impaired rodent plasticity and memory; antibodies prevented selected effects and intact plaque cores were relatively inactive. Forced extract administration demonstrates capacity, not endogenous human species necessity or propagation.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 44 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C45", "text": "STING inhibition improved memory and multiple inflammatory/amyloid/tau features in a double-knock-in model. Broad pathway effects do not identify a sole amyloid-primary or inflammation-primary initiator in sporadic humans.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 45 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C46", "text": "Inducible oligodendrocyte BACE1 deletion reduced plaque burden and restored early neuronal firing in APP knock-in mice; Aβ-depleted conditioned medium lost acute hyperactivity effects. BACE1 is pleiotropic, exposure began in young mice, and neuronal firing is not human clinical progression; injected medium is a separate forced sufficiency test.", "carries_number": false, "load_bearing_for": [ "SC1", "SC2", "SC3" ], "source_ns": [ 46 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status record; selected primary-body sections: sec006, sec007, sec010, sec033. No full-paper or supplement audit.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C47", "text": "Several high-resolution imaging assays localized oligomeric Aβ inside synapses of a plaque-bearing model. Localization and agreement between imaging modalities do not establish synaptic species necessity.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 47 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C48", "text": "APP knock-in time courses showed early mitochondrial hypermetabolism and later synaptic/autophagy abnormalities. Model temporal order does not isolate the causal mediator or establish a universal human sequence.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 48 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C49", "text": "Endothelial Angpt2 deletion lowered amyloid in 5xFAD; vascular and inflammatory pathways accompanied behavioral abnormalities. Overexpression and knockout contrasts have different inferential strength; 5xFAD and vascular pleiotropy limit sporadic-human initiation claims.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 49 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C50", "text": "Early anti-Aβ treatment in APP-SAA knock-in mice reduced plaque and broad disease-associated glial signals, with active glia at residual plaques. The reported markers do not by themselves demonstrate preserved cognition, mediator necessity or complete disease prevention.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3" ], "source_ns": [ 50 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C51", "text": "Medial-temporal tau occurred with aging, while wider cortical tau was associated with amyloid and global decline. Cross-sectional PET supports stage distinctions but cannot prove amyloid-free tau initiates AD or amyloid causes its expansion.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 51 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C52", "text": "DIAN randomized antibodies engaged targets without clinical benefit; gantenerumab moved tau and NfL markers. The primary disease model did not converge, but sensitivity analyses agreed; late dose escalation and no asymptomatic decline limit prevention inference.", "carries_number": false, "load_bearing_for": [ "SC3", "SC4", "SC5" ], "source_ns": [ 52 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status record; selected primary-body sections: S3, S4, S8, S9. No full-paper or supplement audit.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C53", "text": "DIAN baseline cross-sectional data inferred biomarker changes decades before expected symptoms. A prospective cohort label does not turn this baseline analysis into observed within-person chronology; familial scope and an erratum are retained.", "carries_number": false, "load_bearing_for": [ "SC3", "SC4" ], "source_ns": [ 53 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C54", "text": "APOE4-associated BBB injury predicted decline after accounting for measured amyloid and tau. This human prediction is not a vascular intervention or proof that every case is vascular-primary; pathology measurements are imperfect.", "carries_number": false, "load_bearing_for": [ "SC1", "SC4" ], "source_ns": [ 54 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C55", "text": "Small selected DIAN autopsies showed dose-related gantenerumab plaque reduction without detectable tau/glial differences. Nonrandom death/tissue selection and small groups constrain null downstream inference; this is reused DIAN evidence.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3", "SC5" ], "source_ns": [ 55 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "C56", "text": "A longitudinal PSEN2 mutation-carrier case remained clinically resilient with restricted tau pathology. A single case and candidate genetic/environmental explanations do not establish a protective mechanism or population frequency.", "carries_number": false, "load_bearing_for": [ "SC1", "SC3", "SC4" ], "source_ns": [ 56 ], "verification": "verified", "verified_against": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "verified_on": "2026-10-04", "note": "Primary report attribution, not an assertion that the complete nominal mechanism is proved." }, { "id": "CSC1", "text": "Plaque-targeting treatment changes early clinical trajectories, but a primary plaque-specific initiation mechanism is not isolated across AD. Plaques, soluble aggregates and immune clearance are not interchangeable mediators.", "carries_number": false, "load_bearing_for": [ "SC1" ], "source_ns": [ 1, 2, 3, 4, 11, 12, 14, 15, 16, 17, 19, 23, 37, 40, 42, 45, 46, 49, 50, 54, 55, 56 ], "verification": "verified", "verified_against": "Synthesis of separately examined primary evidence cards; framework level is reviewer adjudication, not a reported empirical measurement.", "verified_on": "2026-10-04", "note": "" }, { "id": "CSC2", "text": "Human extracts and selective model manipulations support soluble Aβ toxicity. BACE1 suppression is not oligomer-selective, and human CSF oligomer engagement has not isolated oligomer-specific clinical mediation. Defined mouse hyperactivity causality is retained separately at Ε.", "carries_number": false, "load_bearing_for": [ "SC2" ], "source_ns": [ 13, 21, 24, 41, 43, 44, 46, 47 ], "verification": "verified", "verified_against": "Synthesis of separately examined primary evidence cards; framework level is reviewer adjudication, not a reported empirical measurement.", "verified_on": "2026-10-04", "note": "" }, { "id": "CSC3", "text": "Amyloid can facilitate model injury and modulate tau markers; wider tau spread associates with amyloid in people. Early medial-temporal tau, human resilience, regional/null downstream responses and absent selective human mediation limit universal temporal primacy.", "carries_number": false, "load_bearing_for": [ "SC3" ], "source_ns": [ 3, 11, 12, 19, 21, 23, 24, 29, 34, 35, 36, 37, 38, 42, 43, 45, 46, 48, 49, 50, 51, 52, 53, 55, 56 ], "verification": "verified", "verified_against": "Synthesis of separately examined primary evidence cards; framework level is reviewer adjudication, not a reported empirical measurement.", "verified_on": "2026-10-04", "note": "" }, { "id": "CSC4", "text": "Lifelong APP processing instruments and early-AD randomized clinical effects establish more than association, but neither proves that the full familial primary-initiation cascade explains sporadic disease across stages. This is the scope-matched gate.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 1, 2, 5, 7, 8, 9, 10, 15, 16, 17, 18, 19, 20, 21, 22, 24, 33, 38, 39, 40, 52, 53, 54, 56 ], "verification": "verified", "verified_against": "Synthesis of separately examined primary evidence cards; framework level is reviewer adjudication, not a reported empirical measurement.", "verified_on": "2026-10-04", "note": "" }, { "id": "CSC5", "text": "Positive lecanemab and donanemab clinical comparisons cross Δ, with a defined early amyloid-positive symptomatic population and contrasting stages/agents. Ε records mapped context and pharmacology boundaries. Antibody replications alone are one mechanistic modality; familial instruments do not independently establish this specific treatment subclaim.", "carries_number": false, "load_bearing_for": [ "SC5" ], "source_ns": [ 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 18, 25, 26, 27, 28, 29, 30, 31, 32, 33, 41, 52, 55 ], "verification": "verified", "verified_against": "Synthesis of separately examined primary evidence cards; framework level is reviewer adjudication, not a reported empirical measurement.", "verified_on": "2026-10-04", "note": "" }, { "id": "CH", "text": "Amyloid is a causal contributor in defined early AD, but the universal primary-initiator cascade remains only partly identified.", "carries_number": false, "load_bearing_for": [ "SC4" ], "source_ns": [ 1, 2, 15, 18, 19, 52 ], "verification": "verified", "verified_against": "Bounded synthesis of examined primary results; level is framework adjudication.", "verified_on": "2026-10-04", "note": "" }, { "id": "CN", "text": "Lecanemab primary CDR-SB difference was −0.45 points at 18 months, with both arms worsening.", "carries_number": true, "load_bearing_for": [ "SC5" ], "source_ns": [ 1 ], "verification": "verified", "verified_against": "Complete primary PubMed abstract Results.", "verified_on": "2026-10-04", "note": "" } ], "citation_ledger": [ { "n": 1, "citation": "van Dyck CH, Swanson CJ, Aisen P et al. Lecanemab in Early Alzheimer's Disease. The New England journal of medicine. 2023.", "tier": "A", "kind": "rct", "pmid": "36449413", "doi": "10.1056/NEJMoa2212948", "url": "https://pubmed.ncbi.nlm.nih.gov/36449413/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT03887455", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C1", "CSC1", "CSC4", "CSC5", "CH", "CN" ] }, { "n": 2, "citation": "Sims JR, Zimmer JA, Evans CD et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023.", "tier": "A", "kind": "rct", "pmid": "37459141", "doi": "10.1001/jama.2023.13239", "url": "https://pubmed.ncbi.nlm.nih.gov/37459141/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT04437511", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C2", "CSC1", "CSC4", "CSC5", "CH" ] }, { "n": 3, "citation": "Bateman RJ, Smith J, Donohue MC et al. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. The New England journal of medicine. 2023.", "tier": "A", "kind": "rct", "pmid": "37966285", "doi": "10.1056/NEJMoa2304430", "url": "https://pubmed.ncbi.nlm.nih.gov/37966285/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID37966285", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C3", "CSC1", "CSC3", "CSC5" ] }, { "n": 4, "citation": "Budd Haeberlein S, Aisen PS, Barkhof F et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. The journal of prevention of Alzheimer's disease. 2022.", "tier": "A", "kind": "rct", "pmid": "35542991", "doi": "10.14283/jpad.2022.30", "url": "https://pubmed.ncbi.nlm.nih.gov/35542991/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID35542991", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C4", "CSC1", "CSC5" ] }, { "n": 5, "citation": "Sperling RA, Donohue MC, Raman R et al. Trial of Solanezumab in Preclinical Alzheimer's Disease. The New England journal of medicine. 2023.", "tier": "A", "kind": "rct", "pmid": "37458272", "doi": "10.1056/NEJMoa2305032", "url": "https://pubmed.ncbi.nlm.nih.gov/37458272/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID37458272", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C5", "CSC4", "CSC5" ] }, { "n": 6, "citation": "Honig LS, Vellas B, Woodward M et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. The New England journal of medicine. 2018.", "tier": "A", "kind": "rct", "pmid": "29365294", "doi": "10.1056/NEJMoa1705971", "url": "https://pubmed.ncbi.nlm.nih.gov/29365294/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID29365294", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C6", "CSC5" ] }, { "n": 7, "citation": "Egan MF, Kost J, Tariot PN et al. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. The New England journal of medicine. 2018.", "tier": "A", "kind": "rct", "pmid": "29719179", "doi": "10.1056/NEJMoa1706441", "url": "https://pubmed.ncbi.nlm.nih.gov/29719179/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT01739348", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C7", "CSC4", "CSC5" ] }, { "n": 8, "citation": "Egan MF, Kost J, Voss T et al. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. The New England journal of medicine. 2019.", "tier": "A", "kind": "rct", "pmid": "30970186", "doi": "10.1056/NEJMoa1812840", "url": "https://pubmed.ncbi.nlm.nih.gov/30970186/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT01953601", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C8", "CSC4", "CSC5" ] }, { "n": 9, "citation": "Sperling R, Henley D, Aisen PS et al. Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial. JAMA neurology. 2021.", "tier": "A", "kind": "rct", "pmid": "33464300", "doi": "10.1001/jamaneurol.2020.4857", "url": "https://pubmed.ncbi.nlm.nih.gov/33464300/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID33464300", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C9", "CSC4", "CSC5" ] }, { "n": 10, "citation": "Wessels AM, Tariot PN, Zimmer JA et al. Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials. JAMA neurology. 2020.", "tier": "A", "kind": "rct", "pmid": "31764959", "doi": "10.1001/jamaneurol.2019.3988", "url": "https://pubmed.ncbi.nlm.nih.gov/31764959/", "status_flags": [ "ErratumIn: PMID32658253" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "AMARANTH+DAYBREAK", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C10", "CSC4", "CSC5" ] }, { "n": 11, "citation": "Mintun MA, Lo AC, Duggan Evans C et al. Donanemab in Early Alzheimer's Disease. The New England journal of medicine. 2021.", "tier": "A", "kind": "rct", "pmid": "33720637", "doi": "10.1056/NEJMoa2100708", "url": "https://pubmed.ncbi.nlm.nih.gov/33720637/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT03367403", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C11", "CSC1", "CSC3", "CSC5" ] }, { "n": 12, "citation": "Shcherbinin S, Evans CD, Lu M et al. Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA neurology. 2022.", "tier": "A", "kind": "rct", "pmid": "36094645", "doi": "10.1001/jamaneurol.2022.2793", "url": "https://pubmed.ncbi.nlm.nih.gov/36094645/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT03367403", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C12", "CSC1", "CSC3", "CSC5" ] }, { "n": 13, "citation": "Yang T, Dang Y, Ostaszewski B et al. Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid. Annals of neurology. 2019.", "tier": "A", "kind": "rct", "pmid": "31168802", "doi": "10.1002/ana.25513", "url": "https://pubmed.ncbi.nlm.nih.gov/31168802/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "ABBY+BLAZE", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C13", "CSC2" ] }, { "n": 14, "citation": "Vandenberghe R, Rinne JO, Boada M et al. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimer's research & therapy. 2016.", "tier": "A", "kind": "rct", "pmid": "27176461", "doi": "10.1186/s13195-016-0189-7", "url": "https://pubmed.ncbi.nlm.nih.gov/27176461/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID27176461", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C14", "CSC1", "CSC5" ] }, { "n": 15, "citation": "Jonsson T, Atwal JK, Steinberg S et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012.", "tier": "A", "kind": "primary", "pmid": "22801501", "doi": "10.1038/nature11283", "url": "https://pubmed.ncbi.nlm.nih.gov/22801501/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID22801501", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C15", "CSC1", "CSC4", "CH" ] }, { "n": 16, "citation": "Goate A, Chartier-Harlin MC, Mullan M et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991.", "tier": "A", "kind": "primary", "pmid": "1671712", "doi": "10.1038/349704a0", "url": "https://pubmed.ncbi.nlm.nih.gov/1671712/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID1671712", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C16", "CSC1", "CSC4" ] }, { "n": 17, "citation": "Rovelet-Lecrux A, Hannequin D, Raux G et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nature genetics. 2006.", "tier": "A", "kind": "primary", "pmid": "16369530", "doi": "10.1038/ng1718", "url": "https://pubmed.ncbi.nlm.nih.gov/16369530/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID16369530", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C17", "CSC1", "CSC4" ] }, { "n": 18, "citation": "Tariot PN, Lopera FS, Ríos-Romenets S et al. Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet. Neurology. 2026.", "tier": "A", "kind": "rct", "pmid": "41579901", "doi": "10.1016/S1474-4422(25)00426-0", "url": "https://pubmed.ncbi.nlm.nih.gov/41579901/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID41579901", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C18", "CSC4", "CSC5", "CH" ] }, { "n": 19, "citation": "Quiroz YT, Aguillon D, Aguirre-Acevedo DC et al. APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease. The New England journal of medicine. 2024.", "tier": "A", "kind": "primary", "pmid": "38899694", "doi": "10.1056/NEJMoa2308583", "url": "https://pubmed.ncbi.nlm.nih.gov/38899694/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID38899694", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status record; selected primary-body sections: S7, S13, S14. No full-paper or supplement audit.", "carries_claims": [ "C19", "CSC1", "CSC3", "CSC4", "CH" ] }, { "n": 20, "citation": "Lanoiselée HM, Nicolas G, Wallon D et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS medicine. 2017.", "tier": "A", "kind": "primary", "pmid": "28350801", "doi": "10.1371/journal.pmed.1002270", "url": "https://pubmed.ncbi.nlm.nih.gov/28350801/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID28350801", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C20", "CSC4" ] }, { "n": 21, "citation": "Arber C, Toombs J, Lovejoy C et al. Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Molecular psychiatry. 2020.", "tier": "A", "kind": "primary", "pmid": "30980041", "doi": "10.1038/s41380-019-0410-8", "url": "https://pubmed.ncbi.nlm.nih.gov/30980041/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID30980041", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C21", "CSC2", "CSC3", "CSC4" ] }, { "n": 22, "citation": "Ringman JM, Monsell S, Ng DW et al. Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. Journal of neuropathology and experimental neurology. 2016.", "tier": "A", "kind": "primary", "pmid": "26888304", "doi": "10.1093/jnen/nlv028", "url": "https://pubmed.ncbi.nlm.nih.gov/26888304/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID26888304", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C22", "CSC4" ] }, { "n": 23, "citation": "Bustos V, Pulina MV, Kelahmetoglu Y et al. Bidirectional regulation of Aβ levels by Presenilin 1. Proceedings of the National Academy of Sciences of the United States of America. 2017.", "tier": "A", "kind": "primary", "pmid": "28533411", "doi": "10.1073/pnas.1705235114", "url": "https://pubmed.ncbi.nlm.nih.gov/28533411/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID28533411", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C23", "CSC1", "CSC3" ] }, { "n": 24, "citation": "Perdok A, Van Acker ZP, Vrancx C et al. Altered expression of Presenilin2 impacts endolysosomal homeostasis and synapse function in Alzheimer's disease-relevant brain circuits. Nature communications. 2024.", "tier": "A", "kind": "primary", "pmid": "39613768", "doi": "10.1038/s41467-024-54777-y", "url": "https://pubmed.ncbi.nlm.nih.gov/39613768/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID39613768", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C24", "CSC2", "CSC3", "CSC4" ] }, { "n": 25, "citation": "Swanson CJ, Zhang Y, Dhadda S et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimer's research & therapy. 2021.", "tier": "A", "kind": "rct", "pmid": "33865446", "doi": "10.1186/s13195-021-00813-8", "url": "https://pubmed.ncbi.nlm.nih.gov/33865446/", "status_flags": [ "ErratumIn: PMID35598024" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT01767311", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C25", "CSC5" ] }, { "n": 26, "citation": "Zimmer JA, Sims JR, Evans CD et al. Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension. The journal of prevention of Alzheimer's disease. 2026.", "tier": "A", "kind": "rct", "pmid": "41330788", "doi": "10.1016/j.tjpad.2025.100446", "url": "https://pubmed.ncbi.nlm.nih.gov/41330788/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT04437511", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C26", "CSC5" ] }, { "n": 27, "citation": "van Dyck CH, Sperling R, Johnson K et al. Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025.", "tier": "A", "kind": "rct", "pmid": "41355080", "doi": "10.1002/alz.70905", "url": "https://pubmed.ncbi.nlm.nih.gov/41355080/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT03887455", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C27", "CSC5" ] }, { "n": 28, "citation": "Wang H, Serap Monkul Nery E, Ardayfio P et al. Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025.", "tier": "A", "kind": "rct", "pmid": "40172303", "doi": "10.1002/alz.70062", "url": "https://pubmed.ncbi.nlm.nih.gov/40172303/", "status_flags": [ "ErratumIn: PMID40775664" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID40172303", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C28", "CSC5" ] }, { "n": 29, "citation": "McDade E, Cummings JL, Dhadda S et al. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimer's research & therapy. 2022.", "tier": "A", "kind": "rct", "pmid": "36544184", "doi": "10.1186/s13195-022-01124-2", "url": "https://pubmed.ncbi.nlm.nih.gov/36544184/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT01767311", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C29", "CSC3", "CSC5" ] }, { "n": 30, "citation": "Zimmer JA, Ardayfio P, Wang H et al. Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials. JAMA neurology. 2025.", "tier": "A", "kind": "rct", "pmid": "40063015", "doi": "10.1001/jamaneurol.2025.0065", "url": "https://pubmed.ncbi.nlm.nih.gov/40063015/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "TRAILBLAZER-ALZ+ALZ2+addendum", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C30", "CSC5" ] }, { "n": 31, "citation": "Sur C, Kost J, Scott D et al. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. Brain : a journal of neurology. 2020.", "tier": "A", "kind": "rct", "pmid": "33253354", "doi": "10.1093/brain/awaa332", "url": "https://pubmed.ncbi.nlm.nih.gov/33253354/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "NCT01739348", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C31", "CSC5" ] }, { "n": 32, "citation": "Wessels AM, Lines C, Stern RA et al. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2020.", "tier": "A", "kind": "rct", "pmid": "33049114", "doi": "10.1002/alz.12164", "url": "https://pubmed.ncbi.nlm.nih.gov/33049114/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "APECS+AMARANTH", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C32", "CSC5" ] }, { "n": 33, "citation": "Bateman RJ, Li Y, McDade EM et al. Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial. The Lancet. Neurology. 2025.", "tier": "A", "kind": "rct", "pmid": "40120616", "doi": "10.1016/S1474-4422(25)00024-9", "url": "https://pubmed.ncbi.nlm.nih.gov/40120616/", "status_flags": [ "UpdateOf: PMID39974075", "ErratumIn: PMID40651485" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "DIAN-TU-001+OLE", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status record; selected primary-body sections: S10, S12, S17, S19. No full-paper or supplement audit.", "carries_claims": [ "C33", "CSC4", "CSC5" ] }, { "n": 34, "citation": "Mattsson-Carlgren N, Janelidze S, Palmqvist S et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain : a journal of neurology. 2020.", "tier": "A", "kind": "primary", "pmid": "33068398", "doi": "10.1093/brain/awaa286", "url": "https://pubmed.ncbi.nlm.nih.gov/33068398/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID33068398", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C34", "CSC3" ] }, { "n": 35, "citation": "Roemer-Cassiano SN, Wagner F, Evangelista L et al. Amyloid-associated hyperconnectivity drives tau spread across connected brain regions in Alzheimer's disease. Science translational medicine. 2025.", "tier": "A", "kind": "primary", "pmid": "39841807", "doi": "10.1126/scitranslmed.adp2564", "url": "https://pubmed.ncbi.nlm.nih.gov/39841807/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID39841807", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C35", "CSC3" ] }, { "n": 36, "citation": "Pereira JB, Janelidze S, Smith R et al. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Brain : a journal of neurology. 2021.", "tier": "A", "kind": "primary", "pmid": "34259835", "doi": "10.1093/brain/awab223", "url": "https://pubmed.ncbi.nlm.nih.gov/34259835/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID34259835", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C36", "CSC3" ] }, { "n": 37, "citation": "Xie L, Wisse LEM, Das SR et al. Longitudinal atrophy in early Braak regions in preclinical Alzheimer's disease. Human brain mapping. 2020.", "tier": "A", "kind": "primary", "pmid": "32845545", "doi": "10.1002/hbm.25151", "url": "https://pubmed.ncbi.nlm.nih.gov/32845545/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID32845545", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C37", "CSC1", "CSC3" ] }, { "n": 38, "citation": "Mattsson-Carlgren N, Salvadó G, Ashton NJ et al. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA neurology. 2023.", "tier": "A", "kind": "primary", "pmid": "36745413", "doi": "10.1001/jamaneurol.2022.5272", "url": "https://pubmed.ncbi.nlm.nih.gov/36745413/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID36745413", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C38", "CSC3", "CSC4" ] }, { "n": 39, "citation": "Hall S, Janelidze S, Londos E et al. Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease. Movement disorders : official journal of the Movement Disorder Society. 2021.", "tier": "A", "kind": "primary", "pmid": "33285015", "doi": "10.1002/mds.28370", "url": "https://pubmed.ncbi.nlm.nih.gov/33285015/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID33285015", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C39", "CSC4" ] }, { "n": 40, "citation": "Insel PS, Mattsson N, Donohue MC et al. The transitional association between β-amyloid pathology and regional brain atrophy. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2015.", "tier": "A", "kind": "primary", "pmid": "25499535", "doi": "10.1016/j.jalz.2014.11.002", "url": "https://pubmed.ncbi.nlm.nih.gov/25499535/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID25499535", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C40", "CSC1", "CSC4" ] }, { "n": 41, "citation": "Satir TM, Agholme L, Karlsson A et al. Partial reduction of amyloid β production by β-secretase inhibitors does not decrease synaptic transmission. Alzheimer's research & therapy. 2020.", "tier": "A", "kind": "primary", "pmid": "32456694", "doi": "10.1186/s13195-020-00635-0", "url": "https://pubmed.ncbi.nlm.nih.gov/32456694/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID32456694", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C41", "CSC2", "CSC5" ] }, { "n": 42, "citation": "Saito T, Matsuba Y, Mihira N et al. Single App knock-in mouse models of Alzheimer's disease. Nature neuroscience. 2014.", "tier": "A", "kind": "primary", "pmid": "24728269", "doi": "10.1038/nn.3697", "url": "https://pubmed.ncbi.nlm.nih.gov/24728269/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID24728269", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C42", "CSC1", "CSC3" ] }, { "n": 43, "citation": "Roberson ED, Scearce-Levie K, Palop JJ et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science (New York, N.Y.). 2007.", "tier": "A", "kind": "primary", "pmid": "17478722", "doi": "10.1126/science.1141736", "url": "https://pubmed.ncbi.nlm.nih.gov/17478722/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID17478722", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C43", "CSC2", "CSC3" ] }, { "n": 44, "citation": "Shankar GM, Li S, Mehta TH et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nature medicine. 2008.", "tier": "A", "kind": "primary", "pmid": "18568035", "doi": "10.1038/nm1782", "url": "https://pubmed.ncbi.nlm.nih.gov/18568035/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID18568035", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C44", "CSC2" ] }, { "n": 45, "citation": "Chung S, Jeong JH, Park JC et al. Blockade of STING activation alleviates microglial dysfunction and a broad spectrum of Alzheimer's disease pathologies. Experimental & molecular medicine. 2024.", "tier": "A", "kind": "primary", "pmid": "39218977", "doi": "10.1038/s12276-024-01295-y", "url": "https://pubmed.ncbi.nlm.nih.gov/39218977/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID39218977", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C45", "CSC1", "CSC3" ] }, { "n": 46, "citation": "Rajani RM, Ellingford R, Hellmuth M et al. Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer's disease. PLoS biology. 2024.", "tier": "A", "kind": "primary", "pmid": "39042667", "doi": "10.1371/journal.pbio.3002727", "url": "https://pubmed.ncbi.nlm.nih.gov/39042667/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID39042667", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status record; selected primary-body sections: sec006, sec007, sec010, sec033. No full-paper or supplement audit.", "carries_claims": [ "C46", "CSC1", "CSC2", "CSC3" ] }, { "n": 47, "citation": "Pickett EK, Koffie RM, Wegmann S et al. Non-Fibrillar Oligomeric Amyloid-β within Synapses. Journal of Alzheimer's disease : JAD. 2016.", "tier": "A", "kind": "primary", "pmid": "27258414", "doi": "10.3233/JAD-160007", "url": "https://pubmed.ncbi.nlm.nih.gov/27258414/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID27258414", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C47", "CSC2" ] }, { "n": 48, "citation": "Naia L, Shimozawa M, Bereczki E et al. Mitochondrial hypermetabolism precedes impaired autophagy and synaptic disorganization in App knock-in Alzheimer mouse models. Molecular psychiatry. 2023.", "tier": "A", "kind": "primary", "pmid": "37907591", "doi": "10.1038/s41380-023-02289-4", "url": "https://pubmed.ncbi.nlm.nih.gov/37907591/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID37907591", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C48", "CSC3" ] }, { "n": 49, "citation": "Lee E, Kim S, Zhu CL et al. Angiopoietin-2 aggravates Alzheimer's disease by promoting blood-brain barrier dysfunction and neuroinflammation. Cell reports. 2026.", "tier": "A", "kind": "primary", "pmid": "41529684", "doi": "10.1016/j.celrep.2025.116621", "url": "https://pubmed.ncbi.nlm.nih.gov/41529684/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID41529684", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C49", "CSC1", "CSC3" ] }, { "n": 50, "citation": "de Weerd L, Hummel S, Müller SA et al. Early intervention anti-Aβ immunotherapy attenuates microglial activation without inducing exhaustion at residual plaques. Molecular neurodegeneration. 2025.", "tier": "A", "kind": "primary", "pmid": "40830489", "doi": "10.1186/s13024-025-00878-1", "url": "https://pubmed.ncbi.nlm.nih.gov/40830489/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID40830489", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C50", "CSC1", "CSC3" ] }, { "n": 51, "citation": "Schöll M, Lockhart SN, Schonhaut DR et al. PET Imaging of Tau Deposition in the Aging Human Brain. Neuron. 2016.", "tier": "A", "kind": "primary", "pmid": "26938442", "doi": "10.1016/j.neuron.2016.01.028", "url": "https://pubmed.ncbi.nlm.nih.gov/26938442/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID26938442", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C51", "CSC3" ] }, { "n": 52, "citation": "Salloway S, Farlow M, McDade E et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nature medicine. 2021.", "tier": "A", "kind": "rct", "pmid": "34155411", "doi": "10.1038/s41591-021-01369-8", "url": "https://pubmed.ncbi.nlm.nih.gov/34155411/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "DIAN-TU-001", "access_depth": "full_text_partial", "access_note": "Complete primary abstract and linked-status record; selected primary-body sections: S3, S4, S8, S9. No full-paper or supplement audit.", "carries_claims": [ "C52", "CSC3", "CSC4", "CSC5", "CH" ] }, { "n": 53, "citation": "Bateman RJ, Xiong C, Benzinger TL et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. The New England journal of medicine. 2012.", "tier": "A", "kind": "primary", "pmid": "22784036", "doi": "10.1056/NEJMoa1202753", "url": "https://pubmed.ncbi.nlm.nih.gov/22784036/", "status_flags": [ "ErratumIn: N Engl J Med 2012;367(8):780 (erratum notice has no PMID)" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID22784036", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C53", "CSC3", "CSC4" ] }, { "n": 54, "citation": "Montagne A, Nation DA, Sagare AP et al. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020.", "tier": "A", "kind": "primary", "pmid": "32376954", "doi": "10.1038/s41586-020-2247-3", "url": "https://pubmed.ncbi.nlm.nih.gov/32376954/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID32376954", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C54", "CSC1", "CSC4" ] }, { "n": 55, "citation": "Chen CD, Franklin EE, Li Y et al. Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease. Acta neuropathologica. 2025.", "tier": "A", "kind": "rct", "pmid": "40459787", "doi": "10.1007/s00401-025-02890-7", "url": "https://pubmed.ncbi.nlm.nih.gov/40459787/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "DIAN-TU-001-autopsy-subset", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C55", "CSC1", "CSC3", "CSC5" ] }, { "n": 56, "citation": "Llibre-Guerra JJ, Fernandez MV, Joseph-Mathurin N et al. Longitudinal analysis of a dominantly inherited Alzheimer disease mutation carrier protected from dementia. Nature medicine. 2025.", "tier": "A", "kind": "primary", "pmid": "39930140", "doi": "10.1038/s41591-025-03494-0", "url": "https://pubmed.ncbi.nlm.nih.gov/39930140/", "status_flags": [ "none_found" ], "opened": true, "opened_on": "2026-10-04", "status_checked_on": "2026-10-04", "study_id": "PMID39930140", "access_depth": "abstract_metadata", "access_note": "Complete primary abstract and linked-status metadata examined; no Methods/body/supplement audit claimed.", "carries_claims": [ "C56", "CSC1", "CSC3", "CSC4" ] } ], "independence_basis": { "required": false, "lines": [], "shared_failure_mode_checked": true, "note": "No formal Ζ-or-higher subclaim is assigned. APP genetics and clinical pharmacology fail differently and support bounded causal contribution; repeated antibodies share the modality. Clarity, Study201, TRAILBLAZER phase2/3 and DIAN follow-up/autopsy reports are shared studies; combined-study rows have compound study identifiers rather than independent-line credit." }, "consensus_validation": { "completed": true, "status": "documented_historical_discovery_and_reconciliation", "provider": "Consensus", "provider_mode": "Historical browser/connector use as recorded in the source artifacts", "local_audit_date": "2026-10-09", "primary_comparison_count": null, "reported_usage": [], "grade_changed": false, "score_before": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "56 primary reports examined; 4 selected partial-body examinations. Replication, heterogeneity, shared cohorts, specificity and incomplete correction-body access support Moderate confidence in this bounded adjudication.", "rests_on_non_peer_reviewed_work": false, "rationale": "Scope-matched SC4 returns Γ for primary initiation/generalization; SC5 separately returns Ε for early clinical contribution. Human genetics and clinical perturbations are considered together and are not re-capped as mere association. Their convergence supports bounded amyloid contribution, while sole/primary initiation and exact pathogenic-species mediation remain unresolved." }, "score_after": { "hsef_level": "Γ", "hsef_descriptor": "Mechanistically plausible, partial system support", "confidence": "Moderate", "confidence_rationale": "56 primary reports examined; 4 selected partial-body examinations. Replication, heterogeneity, shared cohorts, specificity and incomplete correction-body access support Moderate confidence in this bounded adjudication.", "rests_on_non_peer_reviewed_work": false, "rationale": "Scope-matched SC4 returns Γ for primary initiation/generalization; SC5 separately returns Ε for early clinical contribution. Human genetics and clinical perturbations are considered together and are not re-capped as mere association. Their convergence supports bounded amyloid contribution, while sole/primary initiation and exact pathogenic-species mediation remain unresolved." }, "independent_blinded_audit": false, "raw_receipts": [ { "path": "deliverables\\hsef_v53_popularity_batch_2026-10-04\\amyloid-cascade\\consensus\\evidence-cards.json", "sha256": "4eb4c0e020595dfbc6c713489b4e0305f6b78708171923d8a84a1cfe3df2cb29" }, { "path": "deliverables\\hsef_v53_popularity_batch_2026-10-04\\amyloid-cascade\\consensus\\evidence-cards.md", "sha256": "7792f1d9707cb9044cc016910e852dfb28453cc32286d1420772a47dcd6dbc04" }, { "path": "deliverables\\hsef_v53_popularity_batch_2026-10-04\\amyloid-cascade\\discovery\\consensus-targeted.json", "sha256": "064410246d56e30815e98a906ab712ab634a93f4b1307327fa058dfe3e71f969" }, { "path": "deliverables\\hsef_v53_popularity_batch_2026-10-04\\amyloid-cascade\\discovery\\consensus.json", "sha256": "eb868f4291f9993c5719e1bb7a3ac2f7b464b30d9d8cc0ae75236175d712780c" }, { "path": "deliverables\\prepublication-enrichment-2026-10-05\\website-series\\amyloid-cascade\\consensus-browser-links.json", "sha256": "605dc9b4b84db9d131184200ca0b8f74a7c6ce5621f35d75439b5834491d2de0" } ], "limitations": "This verifies documented historical use and links the record to the final edition. It adds no primary-source, full-text, independence or verification credit. Original access remains limited to the source-specific record.", "existing_primary_reconciliation": { "slug": "amyloid-cascade", "consensus_used": true, "rawproof": [ "deliverables/prepublication-enrichment-2026-10-05/website-series/amyloid-cascade/consensus-browser.txt", "deliverables/prepublication-enrichment-2026-10-05/website-series/amyloid-cascade/consensus-targeted-check.txt", "deliverables/prepublication-enrichment-2026-10-05/website-series/amyloid-cascade/consensus-browser-links.json" ], "reconciliation_existing": "Yes; 11 timeline primary identifiers cross-checked per dated ledger; 1 selected body check plus 10 abstract excerpts; timeline, gaps, access limits documented.", "primary_sources_matched": [ "1671712", "16369530", "17478722", "22784036", "22801501", "31686034", "36449413", "37459141", "37966285", "38381674", "40120616" ], "limitations": "Selected checks are not complete-paper examinations (ledger says 0 complete papers). Raw Consensus is discovery/provenance, not the independently verified passage evidence." } } }